Early pancreas development and endocrine induction: Ptf1a and VEGF by Wiebe, Peter O.
  EARLY PANCREAS DEVELOPMENT AND ENDOCRINE INDUCTION: 
PTF1A AND VEGF 
By 
Peter O. Wiebe 
 
Dissertation 
Submitted to the Faculty of the 
Graduate School of Vanderbilt University 
in partial fulfillment of the requirements 
for the degree of 
DOCTOR OF PHILOSOPHY 
in  






Professor Richard O’Brien 
Professor Al Powers 
Professor David Wasserman 
Professor David Bader 
Professor Guoqiang Gu 
 ii
ACKNOWLEDGMENTS 
I am forever grateful to my wife, Elizabeth Hackler, who pushed, pulled, 
and prodded me to complete my dissertation. She has always been my devoted 
supporter, encouraging me to focus on accomplishing the requirements for 
graduation. She has always been there for me and I will be forever obliged for 
her unending support. 
I am grateful to the members of the Gannon Lab, past and present. 
Ninche Alston is a good friend and confidant. Laura Wilding Crawford has always 
been generous and kind. I will miss the cheerfulness she brought to our lab. 
Elizabeth Tweedie Ables was inspirational and was always a technical asset to 
our lab. Hongjie Zhang is a good friend and great scientist. I always value her 
insight, both scientific and political. Venus Roper was an asset to our lab and is 
greatly missed. Amanda Ackermann is a stubbornly smart, relentless scientist. 
Maureen is fortunate to have her as part of her group. I am thankful for Yong Ah 
Oh’s technical support. I appreciate Michelle Guney’s collegial behavior and 
scientific insight. She also is distinct in that she is one of few people in the world 
that have read my scientific publications. David Lowe has been a good friend and 
has been a technical cornerstone to this investigation. I will miss the terrible, 
over-the-top humor we shared. 
I would like to thank my committee for their support. There have been 
times when I felt lost and none of my experiments were working, and my 
committee stepped in and put me back on track. I would like to specifically 
acknowledge Richard O’Brien, my committee chair, who has consistently been 
 iii
supportive and available during my doctoral career. I am grateful for his no-
nonsense attitude and advice that has often been very enlightening. He has 
always readily shared reagents and protocols. I would also like to thank his lab 
members past and present for their support, specifically Ken who has spent 
much of his time discussing scientific techniques with me. 
I am very thankful for Al Powers’ support during my doctoral research. He 
has always been very generous with his time helping me clearly think about the 
science behind the experiment I was performing. His unending support and his 
generous supply of resources and technical support have been instrumental in 
providing a nurturing scientific environment. All the members of the Powers lab, 
past and present have always been supportive and collegial. Marcella Brissova, 
Radhika Aramandla, Alena Shostak, Greg Poffenberger, Priyanka Brahmachary, 
Michael Fowler, and Jeannelle Kantz have all treated me like a member of their 
lab. I am thankful to them all for sharing resources and providing me with 
technical assistance. 
I would like to specifically thank David Wasserman for his support. He has 
always made himself available for impromptu meetings and continued to 
encourage me during difficult times. He has always had an uncanny ability to 
breakdown an experiment and to define its strengths and weaknesses. He is also 
wisely able to predict the possible outcomes of a scenario and weight their 
probable implications. He has always been an excellent advisor. 
I appreciate Guoqiang Gu for providing me with mouse lines developed in 
his lab for use in my investigation. This included the Pdx1-GFP mouse line that 
 iv
was very helpful to me when I was learning embryonic dissection techniques. Gu 
and Sui Wang, his student, generously provided technical assistance and shared 
data that expedited this investigation. 
I am thankful for David Bader’s support. His frank, no-nonsense behavior 
often expedited my committee meetings. He was instrumental in the decision-
making process that encouraged experiments to proceed in the face of possible 
failure, since inaction might have greater consequences. I admire his proactive 
take-charge attitude, despite my tendency to be cautious. 
I am grateful to the beta cell biology community, who has been very 
supportive and collaborative throughout this investigation, especially Ray 
MacDonald for generously providing reagents including plasmids and antibodies, 
as well as expert advice. I appreciate Yoshio Fujitani and Chris Wright for sharing 
and providing data to support this investigation. Jay Kormish and Ken Zaret were 
instrumental in performing the chromatin immunoprecipitation on embryonic 
mouse pancreata, which was a key experiment in our investigation. 
I am especially grateful to Roland Stein. He is a kind and intelligent man, 
and has been very generous with his time and resources to help support this 
investigation. He has encouraged his lab members to train me and he has 
supported experiments essential to our investigation. In addition I would like to 
thank Eva Henderson, Jenny Van Velkinburgh, Amanda Vanhoose, and Jeff 
Raum for their training and support of this investigation. 
I appreciate the Molecular Physiology and Biophysics department; the 
division of Diabetes, Endocrinology, and Metabolism; the Beta Cell Biology group 
 v
meeting; and the program in Developmental Biology. These groups provided a 
fertile and enriching environment full of opportunities for me to grow and develop 
as a scientist and a communicator. Rarely has a day past that a seminar was not 
scheduled and available for me to attend. I would like to Roger Colbran and Bob 
Kesterson, as well as the other members of my qualifying exam, for challenging 
me to improve in areas where I was deficient.  
I would like to thank Jon Backstrom for his support during my scientific 
career here at Vanderbilt. As early as my rotation in David Bader’s laboratory, he 
has been supportive of my success. He generously provided time during my 
qualifying exam preparation to discuss the technical aspects of my proposal. 
Later he also provided reagents and technical support for some of the protein 
biochemistry experiments that I was performing.  
I thank the Vanderbilt Molecular Endocrinology Training Program for their 
financial support in the beginning of my dissertation. I would also like to thank 
Maureen Gannon and Al Powers for their continued financial support that has 
made this investigation possible. I also thank Jennifer Skelton, Linda Gower, and 
the staff of the Vanderbilt Transgenic Mouse/Embryonic Stem Cell Shared 
Resource who generated the transgenic animals. They were critical to the 
success of this investigation. 
I would like to thank Maureen Gannon, my mentor. Her life has always 
been busy and full, but yet she has the amazing ability to put everything aside at 
a moments notice to discuss some aspect of my project, or a concern that I have 
regarding one of my experiments. She is incredibly sharp and efficient, which are 
 vi
qualities I have always admired and hope to attain. She has provided several 
opportunities for me to attend scientific meetings, which have enriched my 
scientific experience and have often provided insight within my own project. I was 
fortunate to be part of her lab from the beginning and am certain that many 
successful candidates will prosper in her laboratory. 
 vii
TABLE OF CONTENTS 
Page 
ACKNOWLEDGMENTS................................................................................... ii 
LIST OF FIGURES........................................................................................... x 
LIST OF TABLES...........................................................................................xiii 
I. BACKGROUND AND SIGNIFICANCE ...................................................... 1 
PTF1.......................................................................................................... 8 
Pdx1........................................................................................................... 5 
Pancreatic endothelial cells ..................................................................... 10 
VEGF....................................................................................................... 13 
VEGFR1 .................................................................................................. 17 
VEGFR2 .................................................................................................. 19 
II. PTF1A BINDS TO AND ACTIVATES AREA III, A HIGHLY 
CONSERVED REGION OF THE Pdx1 PROMOTER THAT 
MEDIATES EARLY PANCREAS-WIDE Pdx1 EXPRESSION. ................ 24 
Introduction .............................................................................................. 24 
Materials and Methods............................................................................. 27 
Transgenic Constructs and Generation of Transgenic Mice................ 27 
Characterization of Transgenic Mice. .................................................. 28 
TRANSFAC Analysis........................................................................... 29 
Electrophoretic Mobility Shift Assays (EMSA). .................................... 29 
Transfection Plasmids. ........................................................................ 31 
Transient Transfections. ...................................................................... 32 
Embryonic Dorsal Pancreas and Gut Tube Dissections. ..................... 33 
Ptf1a Chromatin Immunoprecipitation. ................................................ 34 
Results..................................................................................................... 36 
Lineage tracing reveals that Areas I and II drive expression to 
pancreatic endocrine, but not exocrine tissue.................................. 36 
Addition of Area III to Areas I and II is sufficient to drive early 
pancreas-wide expression. .............................................................. 38 
The Area III-containing XhoI-BglII fragment drives expression early 
throughout the Pdx1 domain. ........................................................... 43 
Ptf1a binds to Area III in vitro............................................................... 46 
Binding of the Ptf1a-containing complex to the Area III element 
requires both the E box and TC box. ............................................... 49 
PTF1 is important for Area III-mediated activation............................... 50 
Endogenous Ptf1a binds the Pdx1 promoter in vivo. ........................... 53 
Discussion ............................................................................................... 57 
 viii
Sequences within Pdx1I-II-III direct dynamic Pdx1 expression in the 
pancreas. ......................................................................................... 57 
Sequences in Pdx1 Area III mediate embryonic pancreas-wide 
expression. ...................................................................................... 58 
Area III mediates acinar expression of Pdx1. ...................................... 59 
PTF1 activates Area III and binds to this control region in embryonic 
pancreas. ......................................................................................... 60 
In vivo relevance of Ptf1a binding Area III ........................................... 61 
III. CHARACTERIZATION OF INDUCTION SYSTEMS FOR THE 
TEMPORAL EXPRESSION OF VEGF.................................................... 63 
Introduction .............................................................................................. 63 
Materials and Methods............................................................................. 66 
Transgene generation. ........................................................................ 66 
Transfections. ...................................................................................... 68 
Western blot and ELISA. ..................................................................... 68 
Mice..................................................................................................... 69 
DNA extraction and genotyping. .......................................................... 70 
Tissue preparation and histology......................................................... 72 
Immunohistochemistry......................................................................... 73 
Pancreatic extracts and measurement of insulin content. ................... 74 
Statistical analyses. ............................................................................. 74 
Results..................................................................................................... 75 
Lactose Inducible System.................................................................... 76 
Tetracycline inducible system.............................................................. 84 
Discussion ............................................................................................... 89 
Lactose inducible system .................................................................... 90 
Tetracycline inducible system.............................................................. 93 
IV. NEITHER ACTIVATION OF VEGF RECEPTOR 1 NOR 2 IS 
SUFFICIENT TO INCREASE β-CELL MASS IN THE DEVELOPING 
PANCREAS............................................................................................. 97 
Introduction .............................................................................................. 97 
Transgene generation. ...................................................................... 101 
Mice................................................................................................... 102 
DNA extraction and genotyping. ........................................................ 103 
RNA extraction and analysis.............................................................. 103 
Tissue preparation, histology, and immunohistochemistry. ............... 104 
Morphometric analysis....................................................................... 104 
Physiological assessment of glucose homeostasis. .......................... 104 
Pancreatic extracts and measurement of insulin content. ................. 105 
Statistical analyses. ........................................................................... 105 
Results................................................................................................... 106 
Discussion ............................................................................................. 113 
 
 ix





LIST OF FIGURES 
 
Figure            Page 
1. Events of pancreatic organogenesis......................................................... 3 
2. A simplified model for the role of islet transcription factors in 
endocrine differentiation in the developing pancreas................................ 5 
3. Structure of Pdx1...................................................................................... 6 
4. Dynamic expression pattern of Pdx1 in the developing pancreas and 
foregut. ..................................................................................................... 7 
5. Conversion from pancreatic to duodenal fates by inactivation of Ptf1a. ... 9 
6. Pancreatic budding and endocrine differentiation take place adjacent 
to blood vessels...................................................................................... 13 
7. Exon structures of the vascular endothelial growth factor (VEGF)-A 
mRNA splice variants. ............................................................................ 14 
8. Diagram showing the receptors expressed on VECs and their VEGF 
isoform specificities. ............................................................................... 16 
9. Diagram of VEGFR1 showing cytoplasmic tyrosine phosphorylation 
sites and signaling molecules that bind these sites via their SH2-
domains.................................................................................................. 17 
10. Diagram of VEGFR2 intracellular signaling. ........................................... 20 
11. The complex and overlapping signaling potential of the VEGF family 
of angiogenesis regulators. .................................................................... 22 
12. Model outlining the reciprocal signaling between the vascular 
endothelium and pancreatic cell types during development. .................. 23 
13. Diagram of highly conserved areas within the Pdx1 
promoter/enhancer region. ..................................................................... 25 
14. Lineage tracing of a region that contains the conserved Areas I and II 
(Pdx1PBCre) mediated recombination only in islet endocrine cells of 
the pancreas at postnatal day one (P1).................................................. 38 
15. Expression is restricted to β cells in Pdx1I-II-IIIlacZ adults........................ 39 
 xi
16. Pdx1I-II-IIIlacZ is expressed in both endocrine and acinar cells during 
development. .......................................................................................... 42 
17. Lineage tracing of Area III-containing, Pdx1XBCre-mediated 
recombination throughout the endogenous Pdx1 domain. ..................... 45 
18. Ptf1a-containing complex binds Area III and requires both the E and 
TC box.................................................................................................... 48 
19. Pdx1 Area III activity is dependent on PTF1........................................... 52 
20. PTF1 dependent expression of luciferase reporter plasmids 
transfected into HEK293 (HEK) and AR42j cells. ................................... 53 
21. Ptf1a protein is specifically enriched at Area III and Area IV of the 
Pdx1 promoter. ....................................................................................... 55 
22. Lactose inducible system diagram depicting predicted expression 
outcome and construct design................................................................ 75 
23. Diagram depicting expression cassettes constructed for the testing 
and creation of a transgene that can be controlled by the lactose 
inducible system. .................................................................................... 77 
24. VEGF Expression detected in the media of transfected cells. ................ 80 
25. Southern blot of genomic DNA isolated from putative transgenic 
founder mice harboring the Pdx1 “I3” VEGF transgene.......................... 81 
26. Pancreatic insulin content of transgenic mice compared to wild type 
littermate controls. .................................................................................. 82 
27. Western blot of pancreatic extracts from two month old mice. ............... 84 
28. Transgenic mice for the temporal control of expression within the 
Pdx1 expression domain. ....................................................................... 85 
29. Proliferation of hepatocytes versus sinusoidal cells in response to 
selective VEGFR activation. ................................................................... 99 
30. Representative sections of P1 wild type and Pdx1VEGFR2sel 
transient transgenic pancreata labeled with antibodies for PECAM, 
Insulin, and DAPI.................................................................................. 107 
31. Representative section of P1 wild type and Pdx1-VEGFR1sel transient 
transgenic pancreata labeled with antibodies for PECAM, Insulin, and 
DAPI. .................................................................................................... 108 
 xii
32. Detection of transgene mRNA in P1 pancreata of transgenic animals 
overexpressing VEGFR1sel or VEGFR2sel. ........................................... 110 
33. Total insulin content measured in mice overexpressing VEGF 




LIST OF TABLES 
 
 
Table            Page 
1. Analysis of the tetracycline inducible system using the transgenic 
lines expressing rtTA and tTS under the control of the Pdx1 promoter. . 87 
2. The Kd values and relative binding affinities of wild type VEGF and 






BACKGROUND AND SIGNIFICANCE 
 
 
Diabetes mellitus is a devastating disease suffered by 150 million people 
worldwide. This can be the caused lack of sufficient pancreatic beta cell mass, 
which are crucial for maintaining glucose homeostasis. Fortunately, there is a 
treatment in human clinical trials that may help free diabetics from their insulin 
injection regiment and prevent diabetic complications: islet transplantation. The 
procedure itself requires more than one donor for transplantation for recipients to 
be insulin-injection free, and due to an inadequate supply of islets, 
transplantation will not be available to all diabetics (Ryan et al. 2002). There has 
been some recent limited success making islet-like tissue from stem cells, which 
provides promise for this as a future islet-like source for transplantation, but more 
effort needs to be placed on understanding pancreatic development and islet 
differentiation before this can become a realistic resource for transplantation.  
The pancreas arises from the foregut endoderm and the accompanying 
mesodermally derived mesenchyme just caudal to the liver as one dorsal bud 
and one ventral bud in the human, mouse, and zebrafish (Wessels 1967; Laitio et 
al. 1974; Field et al. 2003). Pancreatic bud formation can be observed as early 
as eight weeks gestation in humans (Wang et al. 2005), embryonic day 9.5 
(Wessels 1967), in the mouse, and by 24 h postfertilization (hpf) in zebrafish 
(Field et al. 2003). The endoderm of the pancreatic bud gives rise to both 
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endocrine and exocrine tissue (Figure 1). The endocrine tissue is composed of at 
least five cell types producing insulin (β-cells), glucagon (α-cells), somatostatin 
(δ-cells), pancreatic polypeptide (PP-cells) and ghrelin (ε-cells), which constitute 
clusters of cells called islets of Langerhans. The exocrine tissue is composed of 
acini that secrete digestive enzymes and ducts that transport the acinar 
secretions into the intestine. In mammals, both pancreatic buds can give rise to 
both tissue types.  
During initial pancreatic outgrowth, both cells expressing insulin and 
glucagon can be detected. The immature insulin cells are unable to properly 
secrete their hormones in response to glucose (Hellerstrom and Swenne 1991). 
These immature cells are not necessary for the development of normal islet 
induction and differentiation (Herrera et al. 1994). It is likely that the pancreatic 
bud provides an environment that allows endocrine cell specification to be 
permitted, but lacks the cues necessary for these cells to properly mature. Later 
during pancreatogenesis, there is a phase of endocrine cell differentiation 
expansion termed the secondary transition. These cells give rise to mature 
endocrine mass and comprise postnatal islets (Pictet et al. 1972; Slack 1995; 
Jensen 2004). The signaling events and transcription factors that are responsible 
for this process are not yet completely understood, but are important for 




Figure 1. Events of pancreatic organogenesis. Development of the dorsal 
rudiment only is depicted after E9.0. Yellow shading indicates the extent of Pdx1 
expression and gray indicates the early-differentiated endocrine cell clusters. 
Differentiation into mature β cells in green and mature acinar cells in red (Kim 
and MacDonald 2002). 
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 Characterization of genetic regulatory elements and the transcription 
factors operating through these elements during pancreas development 
contributes to our understanding of insulin-producing β cell formation. Several 
transcription factors have been described to be involved at different time points 
during pancreatic differentiation (Figure 2). Perturbations in the transcription 
factors that bind important regulatory control elements can lead to defective 
pancreatic function and diabetes (Stoffers et al. 1997; Hansen et al. 2002; 
Schwitzgebel et al. 2003; Beres et al. 2006). Proper development of the 
endocrine and exocrine compartments of the pancreas requires several 
characterized transcription factors, including the homeodomain transcription 





Figure 2. A simplified model for the role of islet transcription factors in endocrine 
differentiation in the developing pancreas. The proposed position for each 
transcription factor is based on its timing of expression, timing of predominant 
functional role, or both. Clearly some factors function at several steps, but a 
single step is shown for simplicity adapted from (Wilson et al. 2003). 
 
Pdx1 
Pdx1 is a homeodomain containing protein initially described in Xenopus 
(Wright et al. 1989). It contains 283 amino acids and has a prediction molecular 
weight of 31 kDa (Figure 3)(McKinnon and Docherty 2001).  Pdx1 is modular in 
structure with it’s homeodomain flanked by proline rich domains, while the 




Figure 3. Structure of Pdx1. Schematic representation of the predicted structure 
of Pdx1 showing the antennapedia-like homeodomain flanked by two proline rich 
regions. The NH2-terminal activation domain comprising three sub-domains is 
also indicated as are a basic residue-rich nuclear localization signal (NLS) within 
helix three of the homeodomain and a pentapeptide motif that interacts with PBX 




Pdx1 is also known as Ipf1, or insulin promoting factor, as it has been 
described a major transcriptional regulator of the insulin gene (Ohlsson et al. 
1993). Pdx1 regulates the expression of additional islet-enriched genes through 
its interaction with their promoter regions. These include GLUT2, glucokinase, 
amyloid polypeptide (IAPP) and somatostatin (reviewed in Melloul 2004). Pdx1 
also regulates genes encoding transcription factors, such as MafA (Raum et al. 
2006) and Pdx1 itself (Gerrish et al. 2004). Pdx1 is expressed very early in 
pancreas development throughout both the dorsal and ventral pancreatic buds 
(Figure 4)(Guz et al. 1995; Gannon and Wright 1999; Li et al. 1999). After birth, 
Pdx1 is expressed at high levels in the insulin-producing β cells within the islets, 
in some somatostatin-producing δ cells, and at lower levels in subpopulations of 
exocrine cells (Figure 4)(Guz et al. 1995; Offield et al. 1996; Wu et al. 1997; 




Figure 4. Dynamic expression pattern of Pdx1 in the developing pancreas and 
foregut. Tracking of Pdx1 expressing tissues in Pdx1+/-(lacZ) embryos. At E9.5, 
dorsal and ventral buds stain for β-galactosidase expression in Pdx1+/-(lacZ) 
embryos. The presumptive duodenum between the buds is also stained. The 
ventral and dorsal buds stain throughout with X-gal by E11.5 in Pdx1+/-(lacZ) 
animals and X-gal staining labels the antral stomach, duodenum, and common 
bile duct (Offield et al. 1996).Digestive organs from Pdx1-(lacZ)/-(lacZ);Pdx1resc 
animals at P1. Pdx1-driven lacZ expression from the Pdx1-(lacZ) null allele is 
detected by X-gal staining (blue). Islets are present along the pancreatic duct at 
P1. Glucagon expression (brown) marking islets from three-month-old Pdx1-(lacZ)/-
(lacZ);Pdx1resc animals (Gannon et al. 2001). Pdx1 driven β-gal expression was 
also detected at lower levels in subpopulations of acinar cells (Wu et al. 1997). 
 
 
Null mutations in Pdx1 in humans and mice result in an apancreatic 
phenotype (Jonsson et al. 1994; Offield et al. 1996; Stoffers et al. 1997). 
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Mutations in Pdx1 have also been identified in a subset of patients with a 
monogenic dominant form of diabetes, maturity onset diabetes of the young 
(MODY4)(Stoffers et al. 1997; Dutta et al. 1998). In mice, Pdx1 haploinsufficiency 
results in decreased β cell function (Dutta et al. 1998; Clocquet et al. 2000; 
Brissova et al. 2002), increased β cell apoptosis (Johnson et al. 2003), and loss 
of Pdx1 specifically from adult β cells leads to diabetes (Dutta et al. 1998). Taken 
together, these studies demonstrate that Pdx1 functions both early in pancreas 
development and later in mature islets. Characterization of Pdx1 regulatory 
regions and the factors that bind to these regions should lead to a better 




The heterotrimeric pancreas transcription factor-1 complex (PTF1) was 
first identified as an activator of exocrine-specific genes (Rose et al. 1994), and is 
comprised of an acinar cell-enriched basic helix loop helix protein (bHLH), Ptf1a 
(p48), a ubiquitous bHLH protein (Krapp et al. 1996), HEB, and the distinct 
mammalian Suppressor of Hairless (RBP-Jκ/CBF1)(Obata et al. 2001) or its 
paralogue (RBP-L)(Beres et al. 2006). The PTF1 complex controls the selective 
transcription of acinar secretory enzymes, such as elastases, carboxypeptidases, 
amylases, and chymotrypsinogens (Harding et al. 1977; Cockell et al. 1989). 
Ptf1a is expressed as early as E9.5 throughout the developing pancreas 
and is essential for pancreas formation and function in both mouse and human 
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(Krapp et al. 1998; Obata et al. 2001; Kawaguchi et al. 2002; Sellick et al. 2004). 
Ptf1a null mice lack a ventral pancreatic bud and show an early arrest in dorsal 
bud outgrowth (Figure 5)(Kawaguchi et al. 2002). Exocrine cells do not develop 
and there is limited endocrine development. The endocrine cells that do form are 
found alongside the pancreatic rudiment (Figure 5)(Kawaguchi et al. 2002), or 
mislocalized to the spleen (Krapp et al. 1998). 
 
 
Figure 5. Conversion from pancreatic to duodenal fates by inactivation of Ptf1a. 
a−d, Macroscopic phenotypes of 18.5-d.p.c. embryos, viewed ventrally (a,c) or 
dorsally (b,d), to observe dorsal or ventral bud−derived cells, respectively. a,b, A 
Ptf1a−cre R26R wildtype control. c,d, A Ptf1a Cre/Cre R26R, Ptf1a homozygous 
null mutant. A dorsal bud−derived pancreatic rudiment is observed (arrows in c,d) 
and expansive areas of cells expressing β-galactosidase cells are found in the 
duodenum (framed). e−h, Histological analysis of pancreatic rudiment from a 
Ptf1a Cre/Cre R26R embryo using thin sections (2 m) to determine the degree of 
overlap of -galactosidase expression and endocrine markers. e, Endocrine 
clusters (arrowheads) are found alongside a pancreatic duct−like epithelium 
(arrows). Almost all duct cells express -galactosidase; insulin- (f) or glucagon-
producing cells (h) are either labeled (arrowheads) or unlabeled (arrows) by X-
gal staining (g) (Kawaguchi et al. 2002). 
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 Ptf1a expression in the early pancreatic primordium requires the adjacent 
mesenchyme including vascular endothelial cells (Yoshitomi and Zaret 2004; 
Jacquemin et al. 2006). The dependence of this transcription factor’s expression 
suggests an early signaling event from the neighboring endothelial cells. Such a 
connection underscores the importance of orchestrating transcription factor 
expression, and that these events may not be cell autonomous, but instead rely 
on extracellular signaling for proper patterning and differentiation. The 
relationship between endothelial cells and pancreatic endoderm is the subject of 
investigation in Chapters II and III. 
 
Pancreatic endothelial cells 
Pancreatic bud outgrowth is initiated at sites in the posterior foregut 
endoderm where it contacts the endothelium of major blood vessels and 
endocrine differentiation initially occurs in cells that have direct contact with 
endothelial cells (Figure 6)(Lammert et al. 2001). For example, at E10.5, insulin 
expression is detected at sites where the dorsal pancreatic bud contacts portal 
vein endothelium (Figure 6). The importance of VECs in pancreatic endocrine 
differentiation has been demonstrated both in tissue recombination experiments 
and in genetically modified mice. For example, E8.5 endoderm cultured in the 
absence of endothelial cells failed to activate either Pdx1 or insulin protein 
expression, whereas when undifferentiated endoderm was cultured in 
combination with dorsal aorta, both Pdx1 and insulin were induced (Lammert et 
al. 2001). Examination of VEGFR2 null mutant mice, which die prior to the 
second wave of endocrine differentiation, revealed that early insulin and 
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glucagon cells fail to develop (Lammert et al. 2001; Yoshitomi and Zaret 2004). 
These mice express most pancreatic/endocrine transcription factors (Pdx1, Hnf6, 
Ngn3, NeuroD, Prox1, and Hb9) with the exception of Ptf1a (Yoshitomi and Zaret 
2004).  Taken together, these data provide support for an endothelial-derived 
endocrine inducing factor(s). Although the identity of this factor(s) is currently 
unknown, it follows that if endothelial cell numbers were to increase, the amount 
of the inducer, and thus the amount of endocrine cells, would also increase. To 
this end, the Melton laboratory generated transgenic mice expressing the 
VEGF164 isoform throughout the entire pancreatic bud using a fragment of the 
Pdx1 promoter (Lammert et al. 2001). Pdx1-VEGF transgenic embryos have 
greatly increased vasculature in the pancreas and a corresponding 3-fold 
increase in islet number and islet area. Ectopic insulin expression was found 
adjacent to the ectopically induced endothelial cells. 
In collaboration with the Powers lab we have found that early 
differentiating pancreatic endocrine cells produce angiogenic factors including 
vascular endothelial growth factor (VEGF) and angiopoietin 1 (Ang-1) and that 
expression of these is maintained in adult islets (Brissova et al. 2006). Other 
investigators have also observed VEGF expression in mature islets (Christofori et 
al. 1995; Rooman et al. 1997; Lammert et al. 2001). These factors are important 
to recruit vascular endothelial cells (VECs) and direct their differentiation into a 
porous fenestrated vasculature. This vasculature associated with the pancreatic 
endocrine tissue is fenestrated to allow for exchange with and sensing of the 
blood, so appropriate amounts of hormones can be rapidly secreted. The 
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continued expression of these factors in adult islets suggests that maintenance of 
a fenestrated endothelium is critical for mature islet function. In addition to islet 
endocrine cells communicating with VECs via secreted growth factors, 
endothelial cells have been shown to signal to the pancreatic epithelium, 
influencing the differentiation of endocrine cells (Lammert et al. 2003; Lammert et 
al. 2003; Yoshitomi and Zaret 2004). Also, analysis of the islet microenvironment 
reveals differences in the basement membranes of islets in association with 
vascular endothelial cells (Nikolova et al. 2006; Nikolova et al. 2007). Together, 
the association between pancreatic endocrine cells and endothelial cells is 




Figure 6. Pancreatic budding and endocrine differentiation take place adjacent to 
blood vessels. (A) Schematic representation of blood vessels (red) relative to 
pancreatic endoderm expressing Pdx1 (blue). The gut tube endoderm is yellow. 
Aortae (a), vitelline veins (v), and gut endoderm (g) are indicated. (B to D) 
Transverse sections through mouse foregut, as indicated in (A). Sections are 
taken from the same 9.5-dpc mouse embryo. (B) Section anterior to the Pdx1 
region. (C) Section through the Pdx1 region. (D) Section posterior to the Pdx1 
region. (E) In the ventral gut tube (g) at E9, Pdx1 expression begins in two 
ventral domains. One domain is shown here. Pdx1 is initiated in the endoderm 
adjacent to the vitelline vein endothelium (v) and not in endoderm adjacent to 
mesenchyme (m). (F) Pdx1 expression begins slightly later in the dorsal 
endoderm adjacent to the fusing dorsal aortae (a). (G) These Pdx1-expressing 
domains are budding from the gut tube at E9.75. (H and I) Adjacent transverse 
sections of the mouse gut tube at E10.5. Scattered cells expressing insulin 
develop in the dorsal pancreatic bud [arrowheads in (H)] adjacent to the right 
vitelline or portal vein as marked by VEGFR2 expression [sites of contact with 





VEGF is a secreted heparin binding, 45 kDa homodimeric glycoprotein 
that acts as a potent endothelial cell-specific mitogen, capable of promoting 
growth and chemotaxis of VECs (reviewed in Ferrara 1999). VEGF belongs to a 
family of proteins that includes six members: VEGF (VEGF-A), placenta growth 
factor (PlGF), and VEGF-B through VEGF-E. All family members contain a 
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characteristic cysteine knot motif which consists of eight regularly-spaced 
cysteine residues (reviewed in Veikkola and Alitalo 1999). VEGF is the most 
abundant family member and is composed of at least four isoforms, of which 
VEGF165 predominates (Cross et al. 2003).  
 
Figure 7. Exon structures of the vascular endothelial growth factor (VEGF)-A 
mRNA splice variants. The gene encoding VEGF-A consists of eight exons that 
encode several different structural motifs. Alternative splicing of a single pre-
mRNA species produces at least four different VEGF-A isoforms that vary in total 
amino-acid number. In humans these correspond to VEGF-A121, VEGF-A165, 
VEGF-A189 and VEGF-A206, of which VEGF-A165 is the predominant form (Cross 
et al. 2003). 
 
 
There is significant genetic evidence supporting a role for VEGF in 
angiogenesis. Mice that lack one allele of the VEGF gene (Carmeliet et al. 1996), 
mice that can only express the VEGF120 isoform (Carmeliet and Collen 1999), 
and mice that have a modest increase in VEGF expression (Miquerol et al. 2000) 
all die during gestation due to vascular defects. Additionally, the VEGFR1 and 
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VEGFR2 knock out mice also die during gestation due to vascular defects (Fong 
et al. 1995; Shalaby et al. 1995). Both VEGF ligand and receptor expression are 
imperative for proper development and function of VECs.  
There are three receptors for VEGF family members, VEGFR1-3, and a 
coreceptor, neuropilin-1. VEGFR1, VEGFR2 and neuropilin-1 are expressed on 
VECs (Figure 8), while VEGFR3 is restricted to lymphatic endothelial cells 
(Makinen and Alitalo 2002). Both VEGFR1 and VEGFR2 have seven 
immunoglobin-like domains in the extracellular region, a single transmembrane 
region, and a consensus tyrosine kinase sequence that is interrupted by a 




Figure 8. Diagram showing the receptors expressed on VECs and their VEGF 
isoform specificities. VEGF121 lacks the heparin and neuropilin binding domain 
and does not bind to the extracellular matrix. VEGF165 and the larger isoforms 
have both the heparin and neuropilin binding sites. The larger the isoform, the 
greater affinity it has for the extracellular matrix. VEGF can be cleaved by 
plasmin during extracellular matrix remodeling producing a soluble VEGF110 N-




Figure 9. Diagram of VEGFR1 showing cytoplasmic tyrosine phosphorylation 
sites and signaling molecules that bind these sites via their SH2-domains. 




VEGFR1 (flt1) is necessary for survival, which was demonstrated by the 
creation of a genetic knock-out mouse. The mice homozygous for this knock-out 
die during embryogenesis due to an overgrowth of endothelial cells (Fong et al. 
1995), which suggests that VEGFR1 might play a negative regulatory role during 
development. Studies in tissue culture cells demonstrated that VEGFR1 
activation by VEGF caused receptor dimerization and transphosphorylation, but 
maximally by only two fold despite the multiple phosphorylation sites (Sawano et 
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al. 1997; Ito et al. 1998). Additionally, mice genetically engineered to lack the 
kinase domain from VEGFR1 survived and had no overt phenotype (Hiratsuka et 
al. 1998). 
Although signaling through VEGFR1 has been demonstrated, it is not 
necessary for survival, suggesting that VEGFR1 must have some other function 
independent of its kinase domain. Indeed, Clark et al demonstrated that the 
extracellular domain of VEGFR1 is produced in vivo and acts as an antagonist of 
VEGF signaling (1998). VEGFR1 has a kd for VEGF of 37 pM (Gille et al. 2001), 
and it has been suggested that since VEGFR1 has a higher affinity for VEGF 
than VEGFR2, that VEGFR1 can act to sequester VEGF and therefore 
negatively regulate endothelial cell growth (Carmeliet et al. 2001). 
In the absence of the VEGFR1 kinase domain, macrophages are unable 
to migrate normally via a VEGF mediated signal (Hiratsuka et al. 1998), 
suggesting that VEGFR1 may have multiple roles depending on the 
developmental stage and cell type expressing the receptor. Additionally, hepatic 
sinusoidal endothelial cells express VEGFR1, and when an agonist specific for 
this receptor is present it causes theses cells to secrete HGF and other growth 
factors in a paracrine fashion (LeCouter et al. 2003). 
Analyses of VEGFR1 activation by VEGF demonstrated that the receptor 
becomes phosphorylated at two major sites, Tyr-1213 and Tyr-1242, and two 
minor sites, Tyr-1327 and Tyr-1333 (Figure 9). Phospholipase C-gamma binds to 
both Tyr-1213 and Tyr-1333, while Grb2 and SHP-2 bind to Tyr-1213, and Nck 
and Crk bind to Tyr-1333 (Figure 9), all in a phosphorylation dependent manor in 
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vitro (Ito et al. 1998). The significance of these interactions has yet to be 
resolved, but it seems likely that they are essential mediators for the cellular 
response to VEGF via VEGFR1. 
 
VEGFR2 
VEGFR2 (kdr; flk1) is also essential for survival, demonstrated by the 
creation of mice with a null allele of this gene. Mice homozygous for VEGFR2 
null allele die embryonically due to the failure of endothelial cells to organize into 
blood vessels (Shalaby et al. 1995). VEGFR2 is the main receptor responsible 
for proliferation, migration and permeability of endothelial cells (Figure 
10)(reviewed in Ferrara et al. 2003). VEGF binds to the second and third 
extracellular IgG-loop of VEGFR2 with a Kd of 75-125 pM (Waltenberger et al. 
1994). It is phosphorylated in several places in response to VEGF ligand binding 
(Figure 10), and the signaling cascade has been more extensively investigated 
than for VEGFR1 (Matsumoto and Claesson-Welsh 2001).  
Proliferation following VEGFR2 activation in endothelial cells is mediated 
by mitogen activated protein kinase (MAPK) pathway via phospholipase C (PLC) 
gamma binding the tyrosine phosphorylated receptor, leading to diacylglycerol 
(DAG) production from phosphatidylinositol, and activation of protein kinase C 
(PKC), which activates Raf via both Ras dependent (Figure 10)(Takahashi et al. 
1999) and independent pathway (Meadows et al. 2001). Ultimately, this results in 
alterations in gene transcription and proliferation (Figure 10). VEGFR2 activation 
also affects endothelial cell permeability. Phosphoinositide 3-kinase (PI3K) is 
 20
activated by VEGFR2 via focal adhesion kinase (FAK) increasing 
phosphatidylinositol (3,4,5)-trisphosphate (PIP3) and activating Rac, which leads 
to increased permeability (Figure 10)(Eriksson et al. 2003). The increased PIP3 
also leads to protein kinase B (PKB; Akt) activation, which activates endothelial 
nitric oxide synthase (eNOS), and the NO production resulting in increased 
permeability (Figure 10)(Dimmeler et al. 1999; Fulton et al. 1999).  
 
 
Figure 10. Diagram of VEGFR2 intracellular signaling. Ligand binding the 
extracellular domain causes receptor dimerization and autophosphorylation of 
specific tyrosine residues. The phosphorylated amino acids provide binding sites 
for SH2-domain containing signaling molecules, which mediate the indicated 
effects on VECs (Cross et al. 2003). 
 
 
There are several mediators of migration of endothelial cells by VEGFR2 
activation. Activated Rac via PI3K has been implicated in migration (Figure 
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10)(Eriksson et al. 2003) as well as increased NO production from eNOS via 
PI3K and Akt/PKB activation (Figure 10)(Dimmeler et al. 1999; Fulton et al. 
1999), which are also involved in permeability via fenestrations and intercellular 
porosity. Cytoskeletal rearrangement necessary for migration includes 
involvement of p38 mitogen-activated protein kinase (MAPK)(Rousseau et al. 
1997), FAK (Qi and Claesson-Welsh 2001), and stress-activated protein kinase-2 
(SAPK)(Rousseau et al. 2000)(Figure 10). 
VEGFR1 and VEGFR2 have been shown to heterodimerize and 
transphosphorylate each other, suggesting that there is some cross-talk between 
these two signaling pathways (Autiero et al. 2003). This initially might seem 
irrelevant since VEGF activates both of these receptors, except that VEGF is a 
family of proteins that each have different affinities for both of these receptors. 
For example, PIGF, a VEGF homolog and family member, binds specifically to 
VEGFR1 and not to VEGFR2 (De Falco et al. 2002), while VEGF-E binds 
specifically to VEGFR2 and not to VEGFR1, and VEGF-A (VEGF) binds to both 




Figure 11. The complex and overlapping signaling potential of the VEGF family of 
angiogenesis regulators. VEGF-A, -B, -C, -D and PLGF bind as indicated to 
VEGFR-1 and/or VEGFR-2, receptor tyrosine kinases whose expression is 
largely restricted to endothelial cells. In adults, the related VEGFR-3 is expressed 
primarily in lymphatic vessels and can demonstrably regulate 
lymphangiogenesis; it may also have a role in developmental angiogenesis 
(Inoue et al. 2002). 
 
 
The evidence is increasing that during both liver and pancreas 
development, endothelial cells produce an instructive signal that induces 
pancreatic endocrine differentiation and morphogenesis (Lammert et al. 2001; 
Matsumoto et al. 2001; Yoshitomi and Zaret 2004). VECs are known to produce 
several different secreted growth factors including: fibroblast growth factor (FGF), 
transforming growth factor β  (TGFβ), Wingless (Wnt), and hepatocyte growth 
factor (HGF)(Lammert et al. 2003). In the liver, a VEGFR1 receptor-selective 
agonist causes these cells to express growth factors in a paracrine fashion. 
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Thus, VEGF signaling through this particular receptor may induce the expression 
of growth factors known to be mitogenic to β cells (Hayek et al. 1995; Otonkoski 
et al. 1996; Garcia-Ocana et al. 2000). These studies highlight the reciprocal 
communication between pancreatic endocrine cells and endothelial cells (Figure 
12). Chapter III and IV present experiments wherein signaling in the pancreatic 
through the VEGF pathway was modified to elucidate its role in pancreatic 
endocrine cell specification and proliferation. 
 
 
Figure 12. Model outlining the reciprocal signaling between the vascular 
endothelium and pancreatic cell types during development. Endocrine cells 
express angiogenic factors that influence migration and proliferation. Endothelial 
cells respond to these signals and preferentially influence endocrine cells in the 
pancreas. The developmental time frame when this can occur and the signaling 









PTF1A BINDS TO AND ACTIVATES AREA III, A HIGHLY CONSERVED 
REGION OF THE Pdx1 PROMOTER THAT MEDIATES EARLY PANCREAS-




 Previous analysis of Pdx1 non-coding regulatory regions identified four 
areas of highly conserved sequence (termed Areas I through IV; each ~300 bp) 
within 7 kb upstream of the promoter (Figure 13)(Sharma et al. 1996; Gerrish et 
al. 2000; Gerrish et al. 2004). Areas I (-2852 to -2547), III (-1973 to -1694), and 
IV (-6422 to -5931) are conserved among humans, rodents, and chickens, while 
Area II (-2247 to -2071) has only been identified within the mammalian orthologs 
(Gerrish et al. 2000; Gerrish et al. 2004). A β-galactosidase (β-gal) reporter 
transgene driven by a 4.6 kb (-4617 to -33) or a 4.3 kb (-4617 to -320) promoter 
fragment, containing Areas I, II, and III, but not Area IV (Figure 13), recapitulates 
the endogenous Pdx1 expression pattern (Stoffers 1999; Gannon et al. 2001). 
Transgene-based complementation experiments on Pdx1 null mice reveal that 
the proximal promoter/enhancer region, excluding Area IV, rescues the 
pancreatic defects caused by Pdx1 deficiency (Boyer et al. 2006). Thus, Area IV 
does not appear to be essential for appropriate temporal control of pancreatic 
Pdx1 expression. In cell lines, Areas I and II are each capable of driving β cell-
specific reporter gene expression independently, while together their β cell-
specific activity is greatly enhanced, suggesting that synergistic interactions 
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between the two regions mediate high level Pdx1 gene expression in islets 
(Gerrish et al. 2000; Van Velkinburgh et al. 2005). Area III does not drive β cell-
selective activity in cell lines (Gerrish et al. 2000).  
 
 
Figure 13. Diagram of highly conserved areas within the Pdx1 
promoter/enhancer region. Area I (stipple, -2852 to -2547 bp), Area II (white, -
2247 to -2071 bp), Area III (gray, -1973 to -1694 bp), and Area IV (dark gray, -
6422 to -5931) are conserved regions among species (Gerrish et al. 2000). 
Labeled horizontal lines below the Pdx1 promoter indicate regions of relevance in 
this investigation. PstI (-3007), XhoI (-2046), BstEII (-2011), and BglII (-994) are 
relevant restriction sites. Numbering is relative to the mouse Pdx1 gene 




 Transgenic analysis of the Pdx1 upstream region identified modules that 
were capable of driving endocrine expression in vivo (Figure 13)(Wu et al. 1997; 
Gannon et al. 2001). The 1 kb PstI-BstEII fragment (Pdx1PB; -3007 to -2011), 
which contains Areas I and II (and none of Area III), drives expression of a β-gal 
reporter transgene exclusively in endocrine cells of embryonic and adult 
pancreas (Gannon et al. 2001). In contrast, the adjacent 3’ 1 kb XhoI-BglII 
fragment (Pdx1XB; -2046 to -994) drives β-gal expression to only β cells of the 
late embryonic and neonatal pancreata, but is not active in the mature adult 
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organ (Gannon et al. 2001). Of the four conserved regions, only Area II showed 
islet-specific activity in transgenic reporter assays when analyzed individually, 
although this activity was detected in only a subset of β cells (Gannon et al. 
2001; Samaras et al. 2002; Van Velkinburgh et al. 2005). Thus, as observed in 
cell lines, Area I and II seem to act together in vivo for optimal Pdx1 expression 
in β cells.  
 Combined cell line and transgenic analyses had revealed only a transient 
endocrine role for the highly conserved Area III in Pdx1 gene regulation. In one of 
four transgenic lines, Area III alone drove transient reporter gene expression in 
developing endocrine cells, and drove expression in scattered cells throughout 
the pancreas in adults (Gannon et al. 2001). Interestingly, deletion of these 
conserved cis regulatory regions, Area I, II, and III, from the endogenous Pdx1 
locus, results in a dramatic impairment in endocrine as well as exocrine tissue 
development at early stages of pancreatic outgrowth (Fujitani et al. 2006). 
Otherwise, prior to the current study, there had been no evidence for a role for 
any of these regions in regulation of Pdx1 expression outside of the pancreatic 
endocrine lineage. Using a combination of biochemical and in vivo lineage 
tracing approaches, we uncovered a role for Area III in Pdx1 expression, 
identified a critical site within this region that binds a Ptf1a-containing complex, 
and established the relevance of this activator for proper pancreatic 
development.  
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Materials and Methods 
 
Transgenic Constructs and Generation of Transgenic Mice 
 Pdx1I-II-IIIlacZ: Areas I, II, and III of mouse Pdx1 (Pdx1I-II-III), encompassing 
nucleotides -3030 through -1696 relative to the start of translation (+1), were 
PCR amplified from a 9 kb XbaI genomic fragment (Offield et al. 1996) and 
directionally subcloned into a modified hsp68lacZpA vector which contains the 
heat shock protein minimal promoter and lacZ expression cassette (Sasaki and 
Hogan 1996). Lower case letters indicate base changes introduced to produce 5’ 
HindIII or 3’ PstI restriction enzyme sites for directional cloning (upstream primer: 
5’-GTAATCCaAgCTTTGCCTGCcG-3’; downstream primer: 5’-
GTCTCTGcagTCTTCAGGGAAAAGAGCCAC-3’). Of six Pdx1I-II-IIIlacZ lines, two 
lines had detectable lacZ expression and were propagated for further analysis 
(see below). Generation of an additional eight transient transgenic mice, 
collected and analyzed at embryonic stages, yielded two more individuals with 
detectable expression, which was similar to the established lines. 
 Pdx1XBCre: the 1 kb XhoI to BglII Pdx1 fragment contains Area III and an 
additional 700 bp of 3’ non-conserved sequence, encompassing nucleotides -
2046 to -994 relative to the start of translation (+1) in the mouse gene 
(Pdx1XB)(Gannon et al. 2001). The XB fragment was subcloned upstream of the 
hsp68 minimal promoter and a Cre recombinase expression cassette (Postic et 
al. 1999). Pdx1XBCre-mediated R26R recombination was similar in all four lines 
generated. 
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 Pdx1PBCre: the Cre recombinase/human growth hormone fusion cDNA 
(Postic et al. 1999) was subcloned into the Pdx1PB-HNF6 plasmid vector 
(Gannon et al. 2000) using EcoRI digestion to replace the HNF6 cDNA, such that 
the Pdx1PB was positioned upstream of the hsp68 minimal promoter and a Cre 
recombinase expression cassette.  
 Pronuclei of one-cell embryos from B6D2F1 (Charles River) females were 
injected with 1–5 pl DNA (3 ng/ml) and embryos implanted into pseudopregnant 
CD-1 (Charles River) females (Hogan 1994). Some F0 founders were sacrificed 
at embryonic stages to analyze the Pdx1I-II-III driven β-gal expression pattern; 
transgenic lines were also generated. Genotyping was by Southern blot analysis 
of genomic DNA from brain (embryos and neonates) or tail (adults) tissue. Pdx1I-
II-IIIlacZ transgenic mice were identified on EcoRI-digested DNA with a lacZ cDNA 
probe. Cre transgenic mice were identified on EcoRI-digested DNA with a Cre 
cDNA probe. 
 
Characterization of Transgenic Mice  
 The morning of vaginal plug was considered to be E0.5. Dissected internal 
organs were fixed, stained with X-gal to detect β-gal, embedded, and sectioned 
(Gannon et al. 2000; Zhang et al. 2005). Immunohistochemical staining for 
glucagon and insulin was as described (Gannon et al. 2000). Pdx1 expression 
was analyzed using a 1:1000 dilution of rabbit anti-Pdx1 (Peshavaria et al. 1994), 
and the Vectastain ABC and DAB kits (Vector Labs). Whole mount images of 
dissected digestive organs and embryos were taken using an Olympus XZS9 
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bifocal dissecting microscope with a Nikon Coolpix 4300 digital camera and a 
Nikon UR-E4 eyepiece adaptor. Images of sections were taken under brightfield 
illumination using an Olympus BX41 microscope and digital camera with 
Magnafire software (Optronics). Image brightness, contrast, and color variations 
were minimally adjusted using Adobe Photoshop 6.0 or PowerPoint (Rossner 
and Yamada 2004). Adjustments were equivalent for all samples that were 
directly compared. 
 
TRANSFAC Analysis  
 The highly conserved region of the mouse Pdx1 fragment ranging from 
nucleotides -3030 to -1694 was examined in silico using default setting for 
putative transcription factor binding sites using the TRANSFAC Matrix table and 
Tfsearch software version 1.3 (http://www.cbrc.jp/htbin/nph-tfsearch). 
 
Electrophoretic Mobility Shift Assays (EMSA)  
 Nuclear extracts were prepared from 8 week old male B6D2F1/J (Jackson 
Labs) mouse pancreata as described in (Shapiro et al. 1988; O'Brien et al. 1995), 
modified for use with whole tissue (Rose et al. 1994). Briefly, whole pancreata 
were homogenized with a Tissuemiser homogenizer in ice-cold lysis buffer [10 
mM Tris-HCl (pH 7.4), 0.1M NaCl, 3 mM MgCl2, 0.5% NP-40, 0.5 mM DTT, 0.5 
mM phenylmethylsulfonyl fluoride (PMSF), 0.5 mg/L N-α-p-tosyl-L-phenyl 
chloromethyl ketone (TPCK), 0.5mg/L N-α-p-tosyl-L-lysine chloromethyl ketone 
(TLCK), 0.6 µM leupeptin, and 2 µM pepstatin]. Homogenate was centrifuged 
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(1000xg, 2 min, 4°C); pellets were resuspended in ice-cold lysis buffer, and 
centrifuged (1000xg, 1 min, 4°C). The pellet was resuspended in ice-cold nuclear 
extraction buffer [20 mM HEPES (pH 7.9), 0.4 M NaCl, 0.90 mM spermidine, 0.2 
mM EDTA, 2 mM EGTA, 25% glycerol, 2 mM DTT, 1 mM PMSF, 0.5 mg/L 
TPCK, 0.5 mg/L TLCK, 0.6 µM leupeptin, and 2 µM lepstatin]. The nuclear 
extract was centrifuged (16,000xg, 1 min, 4°C), and the supernatant was 
collected and stored at -80°C.  
 EMSAs, including antibody supershifts, were performed as described 
(Sawada and Littman 1993; Rose et al. 2001). PTF1 control (PTF1 Ela1; -115 to 
-96 of the rat elastase 1 promoter) upper: 5’-
gatcGTCACCTGTGCTTTTCCCTGC-3’, lower: 5’-
gatcGCAGGGAAAAGCACAGGTGAC-3’. Putative Area III PTF1 binding site (AIII 
PTF1; -1730 to -1709 of the Pdx1 promoter) upper: 5’-
gatcCACAGGTGGCTCTTTTCCCTG-3’; lower: 5’-
gatcCAGGGAAAAGAGCCACCTGTG-3’. Lower case indicates 5’ overhangs for 
radioactive fill-in labeling. Other oligonucleotides are described in Figure 18C. 
Mobility shift binding reactions were 20 µL in volume, prepared on ice, and 
contained: 10 mM HEPES (pH 8.0), 90 mM NaCl, 1 mM EDTA, 0.1 M DTT, 6 µg 
bovine serum albumin, 2 ug poly dIdC, and 40 fmol of labeled probe. When 
specified, 5 µg of pancreatic nuclear extract, 5 µg of MIN-6 nuclear extract (gift 
from Jennifer VanVelkinburg, Vanderbilt University), 1 µL of anti-Ptf1a (Rose et 
al. 2001), or a specified quantity ranging from 0.4 to 40 pmol of non-radioactive 
competitor oligonucleotides was added to the binding reaction (Figure 18). 
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Reactions were incubated for 15 minutes at 30°C. 20 µL of each reaction were 
loaded and resolved at 4°C on a 4.0% non-denaturing polyacrylamide gel (40:1) 




 The following were a generous gift of Ray MacDonald (University of 
Texas, Southwestern Medical Center) and have been described previously 
(Beres et al. 2006): rat elastase1 minimal promoter -92 to +8 in the pGL3 basic 
vector (Promega; -92rEla1p/pGL3); a six copy rat Elastase 1 PTF1 site (A 
element) and elastase1 minimal promoter (A26/pGL3); HEB expressed under the 
control of cytomegalovirus (CMV) promoter (HEB/pcDNA1.1); mouse Ptf1a 
expressed under the control of CMV (pCMV-mp48); human RBP-Jκ expressed 
under the control of CMV (Myc-hRbpsuh/pcDNA3); mouse RBP-L expressed 
under the control of CMV (CMV.RBbpsuh-L). 
Oligos annealing in the pBluescript II (Stratagene) vector 
(ATTAACCCTCACTAAAG) and to the 3’ end of Area III 
(GTCTCTGATTTCTTCAGttAAAAGAGCCACCTtTGCCCGTCAAGGGGCC) 
(Gannon et al. 2001) were used to generate an E box and TC box mutant of the 
PTF1 binding site (-1730 to -1709); the lowercase nucleotides correspond to 
those targeted in other PTF1 binding mutants (Hsieh et al. 1996; Rose et al. 
2001; Beres et al. 2006). Wild type and Area III mutant (Pdx1mIII) sequences 
were subcloned into the HindIII site just upstream of the herpes simplex virus 
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thymidine kinase (TK) minimal promoter driving the firefly luciferase expression 
cassette (TK-Luc) in pGL3 (Promega)(Onuma et al. 2006). Wild type and mutant 
Pdx1I-II-III TK-Luc were generated by subcloning Area I-II spanning sequences 
from the Pdx1I-II-III transgene into either Pdx1III TK-Luc or Pdx1mIII TK-Luc. The 
correctness of the plasmids was verified by restriction digestion and partial DNA 
sequencing. 
 
Transient Transfections  
 The Rattus norvegicus exocrine-derived cell line (AR42J) was obtained 
from ATCC (Manassas, VA), and propagated according to specifications 
provided. Cells were transiently transfected with Lipofectamine 2000 (Invitrogen) 
in 24-well plates, 2 × 105 cells/well (0.8µg DNA/well) according to manufacturer’s 
instructions. Data was analyzed for significance by One-Way ANOVA and 
Tukey’s post-test. 
 The Homo sapiens embryonic kidney-derived cell line (HEK 293) was 
propagated in DMEM with 10%FBS according to specifications provided by 
ATCC. Cells were transiently transfected with Lipofectamine in 24-well plates, 1.5 
× 105 cells/well (0.5µg DNA per well). Equimolar amounts of the wild type and 
Area III mutant TK-Luc plasmids were used at a 1:1 molar ratio with the CMV 
driven expression plasmids. Data was analyzed for significance by Two-Way 
ANOVA and Bonferroni’s post-test. 
 TK driven Renilla luciferase expression plasmid phRL-TK (Promega; 10ng) 
was co-introduced into AR42J and HEK 293 cells to control for transfection 
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efficiency. Renilla and firefly luciferase activity were measured using the Dual 
Luciferase assay (Promega) on cell extracts prepared 40 to 48 hours after 
transfection. Each transfection condition was performed on at least four 
independent occasions. Statistical analysis and graph generation were 
performed using PRISM software (GraphPad). 
 
Embryonic Dorsal Pancreas and Gut Tube Dissections  
 Dorsal pancreas bud dissections were performed as illustrated in Figure 
21 panel A to F. Gut tube dissections were performed as previously described 
(Bossard and Zaret 2000). Tissue purity was assayed by detection of Ptf1a or 
alb1 mRNA isolated from dissected tissues. mRNA from dissected tissues was 
isolated using the RNeasy Micro Kit (Qiagen) and cDNA was synthesized using 
the iScript cDNA Synthesis Kit (Bio-Rad). PCR analysis was performed using iQ 
SYBR Green Supermix (Bio-Rad) according to the manufacturer’s instructions. 
The following primers were used in 25 µL reactions at a concentration of 0.3 µM: 
Ptf1a GGTTATCATCTGCCATCGAGG, GCTGTTTTTCATCAGTCCAGGA, alb1 
AGCACACAAGAGTGAGATCGCC, TGGCATGCTCATCGTATGAGC and Hprt 
GCTTGCTGGTGAAAAGGACCT, TGCGCTCATCTTAGGCTTTGTA. The iCycler 
iQ and Optical System Software version 3.1 (Bio-Rad) were used to define the Ct 
value for each PCR reaction. Ct values of Hprt amplification were subtracted 
from Ct values of Ptf1a or alb1 Ct for normalization. Relative expression was 
calculated as 2(-∆Ct). 
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Ptf1a Chromatin Immunoprecipitation  
 Chromatin isolation and immunoprecipitation for embryo tissues was 
modified from established protocols (Weinmann et al. 2001; Chaya and Zaret 
2004). Dissected material was fixed for 10 min at 25 ºC in 1% formaldehyde in 
PBS, pelleted, transferred to 125 mM glycine in PBS and incubated on ice for 5 
to 10 min. Fixed cells were pelleted, resuspended in RIPA (50 mM Tris-HCl pH 
8.0, 0.15 M NaCl, 0.5% Deoxycholic acid, 0.1% SDS, 1% IgePal CA-630, 5mM 
EDTA, 0.5 mM PMSF, 1mM benzamidine, 5 µg/mL antipain, 5 µg/mL leupeptin, 5 
µg/mL trypsin inhibitor) and disrupted in a tissue homogenizer to liberate nuclei. 
Nuclei were pelleted and resuspended in 50 mM Tris-HCl pH 8.0, 10 mM EDTA, 
0.5 mM PMSF, 1 mM benzamidine, 5µg/mL antipain, 5 µg/mL leupeptin, 5 µg/mL 
trypsin inhibitor and incubated on ice for 10 min prior to being flash frozen and 
stored at -80 ºC. Crude chromatin preparations were pooled from 163 dissected 
dorsal pancreatic buds and 77 gut tubes of E11.5 embryos. These nuclear 
isolates were sonicated to an average size of 150 to 400 bp. Equal amounts of 
chromatin (1 µg as estimated by DNA concentration) were diluted to into RIPA 
(modified to 1mM EDTA) and precipitated by Normal Rabbit IgG (Santa Cruz) or 
anti-Ptf1a rabbit IgG (gift from Ray MacDonald, UT Southwestern). Chromatin-
antibody complexes were precipitated with protein A sepharose (Protein A-
Sepharose CL-4B Amersham Cat N. 17-0780-01). Protein A beads were washed 
with RIPA (modified to 0.5 M NaCl) and eluted with 10 mM Tris-HCl pH 8.0, 1 % 
SDS, 1 mM EDTA for 20 min at 42 ºC. The crosslinks were reversed by 
incubation at 68 ºC overnight and the DNA was digested in 10 mM TrisHCl pH 
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8.0, 0.1 M NaCl, 1 mM EDTA, 1 % SDS, 0.1 mg/mL proteinase K, and 
phenol/chloroform extracted prior to PCR. ChIPed and input material was 
analyzed by PCR with the following primers: Pdx1 Area I 
CTGGGACAGAGTCTCAGCAGAAG and CGTCCTGATAGTCCTCCCTGAT, 
Pdx1 Area II AGCAGCGAGCTTGTTTTTCTG and 
CACTTCTGGTCTAATTGCATGCA, Pdx1 Area III TGCCCCGGCCTTTCA and 
GGGAGAGTGTCTCTGATTTCTTCAG, Pdx1 Area IV 
GCTCCAATGCCATTTGTCAA and TGGATCCTGACTGCGTCTTG, and 
elastase 1 promoter TTGACTTAAAATTTGTTCATTTGT and 
ACCCTCTTTATACGGCTCTT. PCR reactions were analyzed using the 2100 
Bioanalyzer and dsDNA 1000 Lab Chips (Agilent Technologies). PCR product 
concentration and molarity were calculated using 2100 Bioanalyzer Expert 




Lineage tracing reveals that Areas I and II drive expression to pancreatic 
endocrine, but not exocrine tissue  
 
We previously reported that the 1 kb PstI-BstEII fragment (Pdx1PB; -3007 
to -2011), which contains Areas I and II from the Pdx1 locus (and none of Area 
III), drives expression of a β-gal reporter transgene exclusively in endocrine cells 
as early as E11.5 and continuing into adulthood (Gannon et al. 2000; Gannon et 
al. 2001; Van Velkinburgh et al. 2005; Zhang et al. 2005). A specific role for 
Areas I and II in regulating endocrine expression is supported here by lineage-
tracing analysis using Pdx1PBCre mice. Pdx1PBCre transgenic mice were crossed 
with the lineage-independent Gt(ROSA)26Sortm1sor (R26R) reporter strain 
(Soriano 1999) to determine whether Pdx1PB was activated at an earlier stage of 
pancreatic development within a common endocrine/exocrine pancreatic 
progenitor. In this case, we expected to observe β-gal activity in all pancreatic 
bud derivatives (acini, ducts and islets). As shown in Figure 14, Pdx1PBCre-
mediated recombination within the pancreas was detected only in islet endocrine 
cells at postnatal day one (P1). Recombination was also observed in a few 
scattered cells within the stomach and duodenum (sites of endogenous Pdx1 
expression, Figure 14) and ectopically in dorsal root ganglia. When X-gal staining 
was observed in the duodenal lumen, it was present in both transgenic and non-
transgenic neonatal littermates, and is most likely due to endogenous intestinal 
β-gal activity (Gannon et al. 2001). Within the islets, recombination was 
throughout the insulin-expressing β cell core and in some glucagon-expressing 
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cells (Figure 14B). Despite generating only one Pdx1PBCre transgenic line, our 
findings are consistent with our previously published results regarding the 
Pdx1PBhsplacZ transgenic mice, the Pdx1PBCre-ERTM;R26R bigenic mice 
(Gannon et al. 2001; Zhang et al. 2005), and the expression of endogenous Pdx1 
in islets after birth (Guz et al. 1995). Thus, our combined analyses indicate that 
Areas I and II are not sufficient to direct expression to early pancreatic 




Figure 14. Lineage tracing of a region that contains the conserved Areas I and II 
(Pdx1PBCre) mediated recombination only in islet endocrine cells of the pancreas 
at postnatal day one (P1). (A) Whole mount of X-gal stained (blue) P1 digestive 
organs from Pdx1PBCre;R26R showing high levels of expression in islets and 
some cells within the stomach. Arrows indicate different regions of the pancreas 
containing X-gal stained cells consistent with normal islet distribution. X-gal 
staining was sometimes observed in the duodenal lumen of transgenic and non-
transgenic neonatal littermates. (B) Cross-section of X-gal stained P1 pancreas 
tissue labeled with antibodies to glucagon (Gluc) in brown. Arrowheads point to 
cells positive for both glucagon and β-gal. Pancreas (p), stomach (s), intestine (I), 
acinar tissue (a). Top diagram shows schematic of Pdx1PBCre transgene and 
R26R reporter construct for lineage tracing of Cre expressing cells (not to scale). 
 
 
Addition of Area III to Areas I and II is sufficient to drive early pancreas-
wide expression 
 
 Four independent Pdx1I-II-IIIlacZ transgenic mice with detectable 
expression were generated, in which lacZ is under the control of Pdx1PB 
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(containing Areas I and II) plus Area III (Figure 13). Pdx1I-II-IIIlacZ transgenic mice 
showed high levels of β cell-enriched expression in the mature pancreas, but at 
earlier stages showed pancreas-wide expression, at apparently equivalent levels 
throughout the endodermally derived tissue (Figure 15, Figure 16). 
 
 
Figure 15. Expression is restricted to β cells in Pdx1I-II-IIIlacZ adults. (A, B) Whole 
mount pictures of X-gal stained (blue) adult pancreata from two independent 
transgenic lines showing an islet-enriched expression pattern. (C, D) 
Representative cross-sections of X-gal stained adult pancreata counterstained 
with eosin, which was typically detected throughout the β cells (C), but 
sometimes appeared variegated (D). Glucagon-expressing cells are labeled with 
an antibody in brown (Gluc, D). Top diagram refers to transgene used to create 




 Two Pdx1I-II-IIIlacZ lines were propagated and characterized. Adult 
pancreata from both Pdx1I-II-IIIlacZ lines were X-gal stained to assess mature 
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organ expression specificity of the transgene. Both in whole mount and sections, 
a pattern of β-gal activity consistent with islet-specific expression in the pancreas 
was observed, preferentially in β cells (Figure 15). The two Pdx1I-II-IIIlacZ lines 
showed differing levels of expression in the adult (Figure 15A, B), and the 
expression pattern within islets was sometimes variegated (Figure 15C), but both 
lines showed expression within the same cell types. Exocrine expression was not 
detectable in adult pancreata (Figure 15C, D). The expression pattern at this 
stage was similar to that seen in Pdx1PBCre; R26R mice (Figure 14), and to that 
previously reported for the Pdx1PBhsplacZ (Wu et al. 1997; Gannon et al. 2001) 
and Pdx1PBCre-ERTM;R26R transgenic mice (Zhang et al. 2005). 
 Pdx1I-II-IIIlacZ transgenic embryos were examined at E9.5, E10.5, and 
E11.5, the time during which pancreatic buds first become visible and outgrowth 
begins. Pdx1I-II-IIIlacZ expression was undetectable at E9.5, but was detected 
broadly and robustly at both E10.5 and E11.5 within the dorsal and ventral 
pancreatic buds, but not in the adjoining gut tube (Figure 16D, E). Consistent 
with the lack of transgene expression in the antral stomach and rostral 
duodenum, X-gal staining co-localized with Pdx1 protein in the pancreatic region 
at E10.5, but was absent from the Pdx1-labeled stomach (Figure 16C). At E14.5 
and E16.5, whole mount β-gal expression was observed throughout the pancreas 
at relatively equal levels (Figure 16F). In contrast, whole mount analysis at E18.5 
and P1 revealed an expression pattern more consistent with forming islet clusters 
(Figure 16G, H). Examination of sections at these time points showed β-gal 
expression in both exocrine and endocrine cells, however, the level of β-gal 
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expression observed in endocrine cells was more intense than that observed in 
exocrine cells, and expression in exocrine cells was variegated (Figure 16I, J). 
To verify our findings, we collected two additional independent F0 transgenic 
Pdx1I-II-IIIlacZ mice at late embryonic stages, which had patterns of expression 
consistent with our propagated Pdx1I-II-IIIlacZ transgenic lines. Thus, the 
expression of Pdx1I-II-IIIlacZ gradually increases within endocrine cells and 
diminishes from exocrine cells between E14.5 and P1, eventually becoming 
restricted to β cells in adult tissue, similar to endogenous Pdx1 expression within 




Figure 16. Pdx1I-II-IIIlacZ is expressed in both endocrine and acinar cells during 
development. X-gal stained (blue) embryos at E11.5 (A-B) showing expression in 
pancreas and ectopic expression in the neural tube. X-gal staining in the 
developing pancreas at E10.5 (C) and E11.5 (D). Section from an X-gal stained 
E10.5 (E) embryo labeled for Pdx1 protein (brown). Whole mount pictures of X-
gal stained dissected digestive organs at E16.5 (F), E18.5 (G), and P1 (H). 
Section from an X-gal stained E16.5 (I) and P1 (J) embryo. Triangles point to 
blue acinar tissue. Pictures are representative of expression observed in four of 
four independent transgenic mice. Top diagram refers to transgene used to 
create the mice analyzed in this figure (not to scale). Luminal X-gal staining was 
observed in the duodenum of some transgenic and non-transgenic littermates at 
late gestation and in neonates (G). Pancreas (p), spleen (sp), stomach (s), rostral 
duodenal portion of the intestine (I), pancreatic dorsal bud (db) and ventral bud 





 Pdx1I-II-IIIlacZ mice exhibited β-gal activity beginning at E10.5 in the dorsal 
neural tube caudal to the midbrain/hindbrain junction (Figure 16A, B), which was 
observed in all four transgenic animals generated, suggesting that this ectopic 
expression was inherent to the transgene. This expression in the neural tube was 
broader than previously described transgenes containing only area I and II, which 
was found in the dorsal root ganglia (Gannon et al. 2000; Gannon et al. 2001; 
Van Velkinburgh et al. 2005; Zhang et al. 2005). In the two lines characterized at 
adult stages Pdx1I-II-IIIlacZ mice also had low levels of ectopic expression in the 
kidneys and hair follicles, similar to Pdx1PBCre-ERTM;R26R bigenic mice (Zhang 
et al. 2005). Expression was not observed in other sites of endogenous Pdx1 
expression, such as the antral stomach or rostral duodenum (Offield et al. 1996), 
at any time point analyzed.  
 
The Area III-containing XhoI-BglII fragment drives expression early 
throughout the Pdx1 domain  
 
 The Pdx1XB fragment drives reporter gene expression transiently in β 
cells, which was observed at E14.5 and P1, but not in the adult (Gannon et al. 
2001). Earlier embryonic stages were not examined in these transgenic lines. To 
trace the cumulative effect of activity of this fragment throughout development, 
we generated four independent Pdx1XBCre transgenic mice lines. All four lines 
shared the same overall pattern of recombination (Figure 17), although in one 
line recombination was not as robust. We identified cells and their progeny that 
expressed Cre at high enough levels to cause recombination of the R26R 
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reporter (Soriano 1999), even after Pdx1XB activity is reported to have ceased 
(Gannon et al. 2001). In all Pdx1XBCre;R26R transgenic mice, we observed 
recombination throughout the endogenous Pdx1 domain at both E14.5 and P1 
(Figure 17F, G). The pattern of recombination observed in whole mounts 
included pancreas, duodenum, antral stomach, and bile duct, which are all 
tissues that arise from cells expressing endogenous Pdx1 (Offield et al. 1996). 
Analysis of sections from P1 Pdx1XBCre;R26R animals revealed complete 
recombination throughout both the endocrine and exocrine pancreas (Figure 
17C), suggesting an early recombination event. Indeed, examination of earlier 
embryonic stages revealed that the Pdx1XBCre transgene is active in the 
posterior foregut region as early as E9.5. At E10.5, R26R recombination was 
observed in the entire dorsal and ventral pancreatic buds of the dissected 
digestive organs, and was also detectable in the adjoining gut tube (Figure 17A, 
B). By E11.5, R26R recombination was also apparent in the common bile duct 
(Figure 17D), consistent with later stages. Occasionally, whole mice underwent 
ubiquitous recombination, otherwise no ectopic expression was observed; 




Figure 17. Lineage tracing of Area III-containing, Pdx1XBCre-mediated 
recombination throughout the endogenous Pdx1 domain. Whole mount pictures 
of X-gal stained E10.5 (B) and E11.5 (E) embryos, and dissected digestive 
organs at E10.5 (A), E11.5 (D), E14.5 (F), and P1 (G). (C) Cross-section of X-gal 
stained P1 pancreas labeled with antibodies to glucagon (Gluc; brown). Pictures 
are representative of expression observed in four of four independent transgenic 
mice. Top diagram refers to transgene used to create the mice analyzed in this 
figure and R26R reporter construct for lineage tracing of Cre expressing cells 
(not to scale). Dorsal pancreas (d), ventral pancreas (v), liver (L), stomach (s), 
rostral duodenal portion of the intestine (I), bile duct (b), embryonic day (E), 







Ptf1a binds to Area III in vitro  
 Collectively, the data demonstrate that Area III is involved in directing 
early, pancreas-wide Pdx1 expression. Area III sequences were thus analyzed in 
silico using Tfsearch and the TRANSFAC database to identify a potential 
transcription factor(s) responsible for controlling this expression. A PTF1-like 
binding site was found at the 3’ end (nucleotides -1730 to -1709) of Area III, 
which was highly relevant since Ptf1a is co-expressed with Pdx1 throughout the 
pancreatic buds at E10.5 (Kawaguchi et al. 2002). This site had high identity 
within both the E and TC boxes that define Ptf1a-HEB-RBP-Jκ/L (PTF1) activator 
binding (Figure 18C)(Cockell et al. 1989; Rose et al. 2001; Beres et al. 2006), 
whereas a PTF1-like site was not found in Area I or II. 
 Gel shift analyses were performed using the PTF1-like binding site from 
Area III and the well-characterized PTF1-binding site from the elastase 1 gene 
(Ela1; Figure 18)(Rose et al. 2001). Nuclear extracts enriched in PTF1 from adult 
mouse pancreata illustrated that the Area III site formed a complex of similar 
mobility to the Ela1 PTF1 element (Figure 18A, lanes 9 and 12), suggesting that 
the putative Area III PTF1 site bound to the same protein component(s) as the 
Ela1 PTF1 element. Furthermore, the Ptf1a antibody completely retarded the 
mobility of the co-migrating complex of both Area III and Ela1 PTF1 probes 
(Figure 18A, lanes 10 and 13). In contrast, a complex of quite different mobility, 
and insensitive to the Ptf1a antibody, was formed with extracts from the MIN-6 
mouse β cell line, which does not endogenously produce Ptf1a (Krapp et al. 
1996)(Figure 18A, lane 14 and 15). These results suggested that a complex 
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Figure 18. Ptf1a-containing complex binds Area III and requires both the E and 
TC box. (A) Gel shift using the putative PTF1 binding site from Area III or the 
PTF1 binding site from the elastase (Ela1) promoter (closed arrowhead refers to 
specific complex). Addition of Ptf1a antibody (Ab) results in a complete supershift 
of the PTF1 complex bound to both the AIII probe and Ela1 PTF1 probe (open 
arrowhead). Right triangles depict increasing amounts of cold competitor: 10x, 
50x, and 100x. Rectangle represents 100x competitor. (B) Gel shift competition 
using indicated E box or TC box mutant cold competitors. Right triangle depicts 
increasing amounts of cold competitor: 10x, 100x, and 1000x. Rectangles 
represent 1000x cold competitor. (C) Sequences of oligonucleotides used in the 
gel shift experiments. Dashes (-) indicate gaps, and periods (.) indicate homology 
to AIII PTF1 probe. Capital letters indicate conserved nucleotides. 
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Binding of the Ptf1a-containing complex to the Area III element requires 
both the E box and TC box 
  
 A PTF1 complex binding site contains both a bHLH E box (CANNTG; the 
invariant nucleotides are underlined) for Ptf1a-HEB binding and a contiguous TC 
box (TTTCCC) for binding of RBP-J or RBP-L (Figure 18C). The PTF1 site was 
characterized to determine if both the E box and the TC box were necessary for 
PTF1 complex binding in the context of the Area III element. Increasing 
concentrations of mutant oligonucleotides were used in gel shift competition 
experiments to determine the requirement for each of these sites in binding of the 
complex. The PTF1 E box within Area III was modified in several different ways 
predicted to affect bHLH binding. Compared with unlabeled wild type probe, the 
E2 mutant, in which a guanine at position four in the E box was replaced with a 
thymine, was able to efficiently compete for the PTF1 complex only at high 
concentrations (Figure 18B, lanes 8-10). The E1 oligonucleotide contains a more 
severe mutation (the highly conserved cytosine at position one was converted to 
an adenine), and was less able to compete for the PTF1 complex (Figure 18B, 
lanes 5-7). In the E3 mutant, all of the conserved E box nucleotides were 
transposed, resulting in a virtual inability to compete even at the highest level of 
competitor (Figure 18B, lane 15). These data indicate that the Area III E box is 
essential for PTF1 complex formation, and other nucleotides within the element 
may also contribute to PTF1 complex binding. To this end, we generated a 
duplication (Dup) mutant oligonucleotide in which the sequence between the E 
box and the TC box was duplicated, increasing the spacing between the two 
sites a half a DNA helical turn, and thus placing the sites on opposite faces of the 
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double helix (Figure 18C)(Cockell et al. 1989; Rose et al. 2001; Beres et al. 
2006). The spacing between these elements is critical for PTF1 binding. The Dup 
oligonucleotide competed poorly for the PTF1 complex (Figure 18B, lanes 11-
13), consistent with the notion that both the E box and TC box are important for 
PTF1 complex formation, and that transcription factors binding these sites likely 
interact for optimal complex formation. The TC mutant oligonucleotide was based 
on a previous mutation used to eliminate transcriptional activation of the RBP-J 
site (Rose et al. 2001). This mutant oligonucleotide was unable to compete for 
the PTF1 complex, despite having an intact E box, reiterating the importance of 
both the position and presence of an E box and TC box for proper PTF1 complex 
formation in the context of the Area III element (Figure 18B, lane 14). The 
competition patterns demonstrated that Ptf1a-HEB-RBP-Jκ/L are present in the 
Area III Ptf1a-containing binding complex. 
 
PTF1 is important for Area III-mediated activation  
 To determine if the PTF1 site of Area III was involved in Pdx1 promoter 
activation, the activity of a binding defective mutant constructed in the context of 
either a Pdx1III or Pdx1I-II-III reporter was compared to its wild type version in 
transfected AR42j cells. This pancreatic acinar cell line produces both PTF1 
(Cockell et al. 1989; Yasuda et al. 2002) and Pdx1 (Yamagata et al. 2002). The 
PTF1 site mutation significantly reduced Pdx1I-II-III TK-Luc and Pdx1III TK-Luc 
activity (Figure 19A, Figure 20). Moreover, Pdx1III activity was stimulated in a 
PTF1 site-dependent manner upon co-transfection of Ptf1a, HEB, and RBP-Jκ, L 
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in HEK 293 cells, a non-pancreatic cell line that does not endogenously produce 
PTF1 (Figure 19B, Figure 20)(Beres et al. 2006). Experiments performed with a 
reporter driven by six copies of the elastase 1 PTF1 binding site verified the 
PTF1-dependent activity in both AR42J and HEK 293 cell lines (Figure 20). 
Collectively, these results demonstrate that PTF1 is capable of specifically 




Figure 19. Pdx1 Area III activity is dependent on PTF1. (A) Wild type (wt) and 
mutated (mutant) PTF1 binding site TK-Luc reporters were transfected into 
AR42j cells. Activity is expressed as percent Pdx1I-II-III ± SEM. (B) Expression 
plasmids of Ptf1a, HEB, and RBP-Jκ or -L were cotransfected into HEK 293 cells 
with the Area III-containing TK-Luc plasmids. Data is expressed as fold activation 
± SEM over the respective Area III-containing TK-Luc cotransfected with 
insertless expression plasmids. Asterisk (*) indicates significance upon 





Figure 20. PTF1 dependent expression of luciferase reporter plasmids 
transfected into HEK293 (HEK) and AR42j cells. A subset of this raw data was 
used to generate the previous figure (Figure 19). The Elastase min and 6x Ela 
PTF1 site are identical except for the addition of six copies of the Elastase PTF1 
binding site in the latter. Activity mediated by PTF1-Jκ relative to PTF1-L is 
attenuated in the context of the Ela1 PTF1 site, whereas this relative activity is 
equivalent if not greater in the context of the Pdx1 PTF1 site. Empty control 
plasmid or expression plasmids of Ptf1a, HEB, and RBP-Jκ or -L were 
cotransfected into HEK 293 cells with the Area III-containing TK-Luc plasmids as 




Endogenous Ptf1a binds the Pdx1 promoter in vivo  
 To investigate whether Ptf1a bound Pdx1 upstream regulatory sequences 
during pancreatic organogenesis, we developed conditions for performing 
chromatin immunoprecipitation (ChIP) from tissues that were microdissected 
from E11.5 mouse embryos. Similarly staged embryos from Pdx1lacZ/+ knock-in 
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mice (Offield et al. 1996) stained for β-gal served as controls for developing a 
protocol to dissect wild type dorsal pancreatic buds from the gut tube (Figure 21, 
panels A-E). Real-time RT-PCR analysis of RNA revealed that the 
microdissected buds expressed the Ptf1a gene, whereas RNA from the gut tube, 
heart, and liver bud were negative, as expected (Figure 21, panel G). 
Conversely, the Ptf1a-positive buds were negative for the liver gene, albumin1 
(alb1; Figure 21, panel G), also as expected. We pooled 163 such pancreatic 
buds, crosslinked the chromatin in the tissues, and performed ChIP with a Ptf1a-
specific antibody. Pooled gut tubes served as negative controls. The scaled-
down ChIP reactions required analysis of the PCR products on a microfluidics 
workstation; the data depict two analytical runs per PCR reaction. PCR analysis 
of the ChIP products with primers to the elastase 1 gene promoter yielded 
markedly higher signals from the dorsal pancreatic buds than from the gut tube 
control (Figure 21, panel H). These data confirm the validity and specificity of the 
embryonic ChIP assay for Ptf1a. 
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Figure 21. Ptf1a protein is specifically enriched at Area III and Area IV of the 
Pdx1 promoter. A–F: The midgut region (A) and (B) isolated from E11.5 day 
embryos. The region containing the dorsal pancreas was removed (C) and (D) 
and separated from contaminating tissue (E). Pancreatic buds pooled and 
processed for chromatin cross linking and isolation (F). (G) Tissue purity was 
assayed by Ptf1a or alb1 expression. mRNA isolated from dissected organs was 
subjected to real time RT-PCR and normalized to HPRT mRNA. (H) Ptf1a 
chromatin immunoprecipitation was performed on chromatin isolated from E11.5 
dorsal pancreas and gut tube. The data represent the average of two Bioanalyzer 
runs per primer pair set amplified in parallel from single ChIP reactions (IgG or 




 Using primers specific for amplification of each of the previously identified 
highly conserved regions within the Pdx1 promoter (Areas I-IV), we next 
analyzed whether Ptf1a interacted specifically with Area III or any of the other 
known regulatory regions. Strikingly, both Areas IV and III exhibited strong 
binding by Ptf1a in E11.5 embryonic pancreatic buds, compared to the gut tube 
controls. By contrast, the islet-specific Areas I and II did not exhibit binding to 
Ptf1a. These data further support a role PTF1 in expression of Pdx1 in early 
exocrine and endocrine progenitors. 
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Discussion 
 The present study provides further insight into the dynamics of Pdx1 
regulation during pancreatic development by illustrating that the early pancreatic 
developmental regulator, PTF1, serves in Area III-mediated activation. Prior to 
the current study, a role for Area III in Pdx1 gene regulation had not been 
established, despite the high degree of sequence conservation within this region 
among vertebrates (human, mouse, and chicken). In cell lines, Area III, and the 
larger XhoI-BglII fragment (Pdx1XB) in which it is located, were incapable of 
directing β cell-selective reporter gene activation (Wu et al. 1997; Gerrish et al. 
2000), suggesting that these sequences might participate in other aspects of 
Pdx1 gene expression. In transgenic analyses, however, Pdx1XB drove lacZ 
expression exclusively to β cells at E14.5 and P1, leading us to conclude that 
sequences within this fragment did indeed participate in β cell-specific regulation 
of Pdx1, although this activity was transient (Gannon et al. 2001). Here we 
provide evidence for Area III facilitating the early and broad expression of Pdx1 in 
pancreatic buds. 
 
Sequences within Pdx1I-II-III direct dynamic Pdx1 expression in the pancreas 
 The Pdx1I-II-IIIlacZ transgene differs from the previously published 
endocrine-specific Pdx1PBhsplacZ only in the addition of Area III. Pdx1I-II-IIIlacZ 
was expressed throughout the pancreatic buds in precursors to all cell types at 
E10.5; as development proceeded expression was gradually diminished in acinar 
cells and intensified in endocrine cells. Thus, sequences within Area III likely 
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confer early pancreas-wide expression to the islet endocrine-specific Pdx1PB 
fragment. Pdx1I-II-III was unable to drive expression within the Pdx1 domain 
outside the pancreas (the antral stomach, rostral duodenum, or common bile 
duct). These expression data are consistent with the phenotype of mice 
containing a global deletion of Pdx1I-II-III (Pdx1∆I-II-III) in which Pdx1 expression is 
dramatically reduced in the pancreatic buds, but is essentially normal in stomach 
and duodenum(Fujitani et al. 2006). Consequently, Pdx1I-II-III deletion resulted in 
limited pancreatic bud outgrowth and differentiation with little effect on stomach 
and duodenum, in contrast to the global Pdx1 deletion (Larsson et al. 1996; 
Offield et al. 1996). 
 
Sequences in Pdx1 Area III mediate embryonic pancreas-wide expression 
 Similar to Pdx1I-II-III reporter expression, the Pdx1XB fragment drove Cre 
recombinase activity throughout the pancreatic buds early in pancreatogenesis. 
The extent of recombination observed in Pdx1XBCre;R26R mice is reminiscent of 
that mediated by Pdx1Cre (Gu et al. 2002), in which Cre is driven by a 5.5 kb 
Pdx1 promoter fragment, which contains sufficient sequence to recapitulate the 
endogenous Pdx1 expression pattern (Stoffers 1999; Gannon et al. 2001). In 
contrast to the expression driven by Pdx1I-II-III, Pdx1XBCre-mediated 
recombination was also detected at high levels in other areas of endogenous 
Pdx1 expression (antral stomach, common bile duct and rostral duodenum). The 
conserved region in common between the Pdx1I-II-III and Pdx1XB fragments is 
Area III (Figure 13), suggesting that sequences within this region are responsible 
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for the early, broad expression of Pdx1 within the pancreas. The region 3’ to Area 
III within the Pdx1XB fragment shows no significant sequence conservation 
between species and is incapable of driving robust lacZ expression to Pdx1-
producing cell types in vivo (Gerrish et al. 2000; Gannon et al. 2001). It is 
possible that antral stomach and duodenal expression are normally driven by 
Area III in vivo, but repressed by sequences within the Pdx1PB fragment in the 
Pdx1I-II-III transgene. This seems unlikely, however, given the phenotype of the 
Pdx1∆I-II-III mice, where in the stomach and duodenum only the enteroendocrine 
cell are affected, specifically a 50% reduction in stomach gastrin cells and 
duodenal GIP cells. Alternatively, sequences 3’ to Area III within the Pdx1XB 
fragment may mediate extra-pancreatic expression of Pdx1, but require 
interaction with factors binding Area III to stabilize, or enhance their activity. To 
date, a duodenal or gastric regulatory element has not been identified in the 
Pdx1 gene. Our in vivo transgenic analysis supports a role for Area III in 
regulation of early, broad expression of Pdx1 throughout the pancreatic bud 
epithelium.  
 
Area III mediates acinar expression of Pdx1 
 Acinar expression of β-gal has not been observed in any mouse line 
carrying transgenes driven by the Areas I and II-containing Pdx1PB fragment 
[Pdx1PBhsplacZ (Wu et al. 1997; Gannon et al. 2001; Van Velkinburgh et al. 
2005), Pdx1PBCre (this study), or Pdx1PBCre-ERTM (Zhang et al. 2005)], 
suggesting that elements within Area III are responsible for endogenous Pdx1 
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acinar expression. Since Ptf1a expression is initially expressed broadly 
throughout the pancreatic buds but becomes restricted to acinar tissue, and is 
capable of binding to sequences upon which Area III activity is dependent, we 
hypothesize that the dynamic changes in Pdx1 expression within acinar tissue 
are mediated, at least in part, by PTF1. Recent studies indicate that expression 
of another component of the PTF1 complex, the mammalian Suppressor of 
Hairless orthologue RBP-Jκ/L, is also developmentally regulated. RBP-Jκ is more 
highly expressed during embryonic pancreas development, while RBP-L is 
exclusively found in adult pancreata (Beres et al. 2006). As RBP-Jκ and RBP-L 
differ in their transcriptional activity (Beres et al. 2006), this developmental switch 
in the TC box binding factor may explain the change in acinar Pdx1 expression. 
 
PTF1 activates Area III and binds to this control region in embryonic 
pancreas 
 
 PTF1 was a likely candidate for early, broad regulation of Pdx1, since its 
pancreas-specific component, Ptf1a, is expressed pancreas-wide as early as 
E9.5 (Obata et al. 2001; Kawaguchi et al. 2002), correlating well with the early 
pancreatic pattern of β-gal expression we observed in the Pdx1I-II-IIlacZ (Figure 
16D, E) and the Pdx1XBCre;R26R mice (Figure 14A, B). Also, the ectopic β-gal 
activity exhibited by the Pdx1I-II-IIIlacZ mice in the dorsal neural tube at E10.5 is 
identical to β-gal expression in the Ptf1aCre/+;R26R mouse in those regions 
(Kawaguchi et al. 2002; Glasgow et al. 2005). Analysis of Area III in silico 
revealed a putative PTF1 site: a conserved CANNTG (E box) and TTTCCC (TC 
box) separated center to center by one turn of DNA (Rose et al. 2001). Ptf1a 
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present in nuclear extracts from adult mouse pancreata bound the putative PTF1 
site in Area III with relatively high affinity (Figure 18), and activity mediated by 
Area III was dependent on this site (Figure 19). In vivo relevance of the PTF1 site 
within Area III is demonstrated by the binding of endogenous Ptf1a to Area III 
within the endogenous Pdx1 promoter in developing pancreatic buds at E11.5 
(Figure 21). Our data do not exclude the possibility that other transcription factors 
affect transcription of Pdx1 during early pancreatic bud formation and outgrowth 
(Boyer et al. 2006; Poll et al. 2006), but suggest that PTF1 activates, at least in 
part, early pancreas-wide expression of Pdx1 through Area III.  
 The significance of Ptf1a binding to Area IV remains to be determined. 
The role of Area IV in regulation of Pdx1 gene expression is only now beginning 
to be addressed. Pdx1 upstream regulatory sequences lacking Area IV are 
capable of driving reporter transgene expression in a pattern temporally and 
spatially indistinguishable from endogenous Pdx1 (Stoffers 1999; Gannon et al. 
2001). Transgene-based complementation experiments on Pdx1 null mice, 
suggest however, that Area IV is required for appropriate levels of Pdx1 
expression in the postnatal stomach and duodenum, although it is not required to 
rescue the pancreatic defects caused by Pdx1 deficiency (Gannon 2001; Boyer 
et al. 2006).  
 
In vivo relevance of Ptf1a binding Area III 
 In vivo deletion of Areas I-II-III from the Pdx1 promoter results in a 
dramatic arrest in pancreas development, similar to that observed in the global 
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Pdx1 null mice (Offield et al. 1996; Fujitani et al. 2006). Since we show that 
Areas I and II are only active in endocrine tissue within the pancreas (Figure 14), 
the failure of the pancreas to develop in the Pdx1∆I-II-III mice is most likely due to 
the loss of Area III, suggesting that sequences within Area III, in particular the 
PTF1 site, are important for expression in the developing pancreas. Pdx1 
expression precedes and is in a broader domain within the posterior foregut than 
Ptf1a expression. In Ptf1a null mice, Pdx1 expression is maintained in the dorsal 
pancreas (Kawaguchi et al. 2002). Taken together, these data suggest Ptf1a is 
not necessary to initiate Pdx1 expression in the pancreas, but is involved in 
maintaining or augmenting Pdx1 expression within the developing pancreatic 
buds. We would predict that removal of Area III containing the PTF1 binding site 
in vivo would result in an apancreatic phenotype without affecting the 
development of other tissues and cell types in which Pdx1 is expressed, similar 




CHARACTERIZATION OF INDUCTION SYSTEMS FOR THE TEMPORAL 





The pancreas derives from dorsal and ventral outgrowths of the 
endodermal epithelium of the posterior foregut. During mid-gestation in the 
mouse, from embryonic day E13.5-16.5 the numbers of endocrine cells increase 
greatly but remain as small clusters of cells closely associated with the ducts. 
The signals stimulating the increase in endocrine differentiation at this time have 
not yet been determined. At E18.5, endocrine clusters begin to lose their 
proximity to the ductal epithelium and coalesce to form islets. In the mouse, 
these islets are composed of a core of β cells surrounded by a mantle of α, δ, ε, 
and PP cells. They express insulin, glucagon, somatostatin, ghrelin, and 
pancreatic polypeptide, respectively. 
Vascular endothelial cells play an integral role in pancreatic endocrine cell 
development. Indeed, in embryos lacking endothelial cells, insulin-expressing 
cells are absent (Lammert et al. 2001; Yoshitomi and Zaret 2004). Conversely, if 
endothelial cells recruited to the pancreas during development are exposed to 
excessive signaling by overexpression of VEGF in the pancreas, then the 
number of endothelial cells increases resulting in a significant increase in insulin 
positive cells (Lammert et al. 2001). It is thought that in the developing pancreas 
a reciprocal inductive event exists whereby endothelial cells secrete a factor that 
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induces pancreatic endocrine cell formation, and the endocrine cells in turn 
secrete factors that actively recruit vascular endothelial cells (Figure 
12)(Lammert et al. 2003).  
Pancreatic endocrine cells normally express elevated levels of VEGF 
during embryogenesis, while vascular endothelial cells express VEGFR1 and 
VEGFR2 (Christofori et al. 1995). Elevated VEGF ligand and its receptors, 
VEGFR1 and VEGFR2, expression continues throughout islet formation and are 
maintained during adulthood (Christofori et al. 1995). Studies show that VEGF 
signaling is important in maintaining islet vasculature. Two independent groups 
examined conditional VEGF-A knockout mice, one examining VEGF loss of 
function in the pancreatic β cells using the RIP-Cre transgene and the other 
examining VEGF loss of function in the entire pancreas using the Pdx1-Cre 
transgene. Both of these groups found that if VEGF expression is reduced, then 
the islet vasculature is significantly reduced (Inoue et al. 2002; Lammert et al. 
2003). Although the average islet size was smaller in these conditional 
knockouts, neither of these manipulations resulted in a profound pancreatic 
endocrine cell differentiation defect that is expected if endothelial cells are critical 
to endocrine development. This mild phenotype may be due to compensation by 
other VEGF genes expressed in the pancreas (Inoue et al. 2002) and 
compensation by VEGF-A expression derived from the mesenchymal cells in the 
pancreas, since only half of the VEGF-A mRNA expressed in the conditional 
knock-out pancreas originates from a recombined allele (Lammert et al. 2003) 
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Since pancreatic overexpression of VEGF has been shown to increase the 
total pancreatic endocrine mass (Lammert et al. 2001), we sought to determine 
whether this was the result of increased specification of pancreatic endocrine 
progenitors, proliferation of pancreatic endocrine progenitors, proliferation of 
differentiated pancreatic endocrine cells, or a combination of these mechanisms. 
More specifically, we attempted to employ an inducible expression system to 
control temporal expression of VEGF in the pancreas during different 
developmental stages. By controlling VEGF overexpression during discrete 
periods of pancreatic development, the window of competence of the endothelial 
cells and the pancreas to respond to these signals would be elucidated, and the 
genes and signals sufficient to induce pancreatic endocrine cell differentiation in 
vivo may be uncovered. This may aid in improving the recapitulation of islet 
formation in vitro from fetal pancreatic ducts or stem cells, experimental sources 
of islets for transplantation (Lechner and Habener 2003). This chapter chronicles 
the cassettes and transgenic animals created and characterized in an attempt 
implement exogenous temporal control over pancreas-wide VEGF transgene 
expression. 
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Materials and Methods 
 
Transgene generation 
 Pdx1PBlacOLacZ: The LacZ responder transgene was generated by 
replacing the HNF6 cDNA from the PdxPBlacOHNF6 vector with the LacZ coding 
region (Elizabeth Tweedie, Vanderbilt University). This vector contained three 
tandem copies of the lactose operator (lacO) sequence 220bp downstream of the 
transcription start site.  
Pdx1PBlacOVEGF: The vector containing the coding sequence for human 
VEGF-165 with the internal myc tag (VEGF-myc) was previously characterized 
(Chavand et al. 2001). An HA tag IRESII eYFP (Clonetech) was subcloned to 
replaced the HNF6 coding region in the PdxPBlacOHNF6 plasmid. The resulting 
vector was digested with BclI and EcoRI to remove the HA tag coding region and 
replaced with VEGF-myc digested with BamHI and EcoRI. Although, this vector 
was generated, it was only used to create subsequent transgenes. 
Pdx14.3hsppolyA: A 9kb XbaI-XbaI Pdx1 genomic fragment was digested 
with XbaI, blunted with T4 DNA polymerase, then digested with SacI to generate 
the 4.3kb Pdx1 fragment (Gannon et al. 2001). This fragment was subcloned into 
the SmaI/SacI digested phsppolyABSSKII plasmid provided by the Hogan Lab 
(Sasaki and Hogan 1996) to generate an empty expression cassette driven by 
the 4.3kb Pdx1 promoter. Although, this vector was generated, it was only used 
to create subsequent transgenes. 
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Pdx14.3lacOVEGF: A SpeI digestion fragment of the Pdx14.3hsppolyA 
vector was replaced with a SpeI digested fragment of the VEGF-myc cassette 
from Pdx1PBlacOVEGF, resulting in a dicistronic VEGF-myc, YFP expression 
cassette driven by the 4.3kb Pdx1 promoter under the control of three tandem 
lacO sequences. The vector served as a control representing our original design 
strategy.  
Pdx14.3I3VEGF: To create this cassette, the Pdx14.3lacOVEGF was 
modified such that the three tandem lacO sequences were removed and the 
intron was replaced with a commercially available intron containing three 
operator sequences (Lacswitch, Stratagene).  
Pdx14.3RSVVEGF: To create this cassette, the Pdx14.3lacOVEGF was 
modified such that the HSP68 minimal promoter, β-globin intron, and the lactose 
operator sequences were replaced with the commercially available RSV minimal 
promoter and intron containing strategically positioned lactose operator 
sequences (Lacswitch, Stratagene).  
Vector constructs were assembled using standard molecular biology 
techniques (Russell 2001), and were verified by restriction digestion and partial 
sequencing. The transgenes cassettes were maxiprepped and purified by CsCl 
ultracentrifugation (Russell 2001). The cassettes were released from the vector 
backbone by NotI restriction digestion, isolated by gel electrophoresis, and 
purified by gelase extraction (Russell 2001). The DNA was measured via 
spectroscopy and provided to the Vanderbilt Transgenic Mouse / ES Cell Shared 
Resource for transgenic mouse generation. Pronuclei of one-cell embryos from 
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B6D2F1 (Charles River) females were injected with 1–5 pl DNA (3 ng/ml) and 




 Transient transfections were performed in HEK293 (a gift from Roger 
Colbran, Vanderbilt University) and βTC3 (a gift from Al Powers, Vanderbilt 
University) cells using 3 µL of Fugene (Roche) per µg of plasmid DNA according 
to manufacturer’s specifications. Culture media containing 1 mM IPTG was used 
to derepress expression in cotransfections (Cronin et al. 2001). Culture media 
was collected and stored at -80°C. Protein was measured in these fractions using 
a Bio-Rad Protein Assay immediately prior to their use in either ELISA’s or 
western blots. 
 
Western blot and ELISA 
 Protein fractions isolated from transiently transfected cells or from 
pancreata were resolved by SDS PAGE under reducing conditions according to 
manufacturer’s specifications (Bio-Rad). Blots were probed with either mouse 
anti-myc (1:100, 9E10, Abcam) or Rabbit anti-hVEGF (1:50, Lab Vision, Ab-8). 
VEGF expression was quantified by using an ELISA specific for human VEGF 




An inbred hybrid line (B6D2; Jackson Labs) was used for all expression 
studies. Mice ubiquitously overexpressing the lactose repressor (lacI) under the 
control of the β-actin promoter were obtained from Heidi Scrable (University of 
Virginia) and have been previously described (Cronin et al. 2001). Transgenic 
mouse lines (PTA), which express the tetracycline activator (rtTA) and 
suppressor (tTS) under the control of the Pdx1 promoter, were obtained from 
Guoqiang Gu (Vanderbilt University). Transgenic LacZ reporter tetracycline-
responsive mice were provided by Al Powers (Vanderbilt University), and have 
been described previously (Ward et al. 2004; Ward et al. 2004).  
When indicated, doxycycline (Sigma) in 10% sucrose was administered in 
the drinking water of animals throughout the duration of pregnancy. Doxycycline 
solution was freshly prepared from doxycycline salt every 2-3 days and kept in 
amber containers to protect it from degradation. Deprivation caps were employed 
to eliminate other water sources during administration. 
For embryonic analyses, the morning of the vaginal plug was considered 
E0.5. Mice were maintained on mouse chow 5015 (24% fat, 57% carbohydrates, 
19% protein; TestDiet) ad libitum. All mouse studies were performed in 
accordance with the Vanderbilt Institutional Animal Care and Use Committee 
guidelines under the supervision of the Division of Animal Care. 
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DNA extraction and genotyping 
Brain (embryos and early perinatal mice), tail (post-natal mice), or ear-
punch (post-natal mice) samples were used to prepare DNA for PCR genotyping. 
Samples were digested overnight at 55°C in nuclei lysis buffer (brain and tail 
samples; Promega) or Lab Buffer 3A (ear-punch samples; 20 mM Tris pH 8.0, 
100 mM KCl, 0.2 mM EDTA pH. 8.0, 1% NP-40, 1% Tween-20) with 30 µg/mL 
Proteinase K (Fisher). For brain and tail samples, DNA was extracted using 
organic solvents by standard methods (Hogan 1994). Ear-punch samples were 
prepared for PCR by further digesting samples with 30 µg/mL RNAase A at 37°C 
for 1 hour, then inactivating at 95°C for 10 min. Following centrifugation of 
undigested material (10 min at 13,000 rpm), DNA was stored at 4°C.  
To determine genotypes by Southern blotting we used standard methods 
(Russell 2001). Transgenes containing the YPF cDNA were genotyped using the 
PstI/MscI 550bp YFP fragment to screen for the 3.4kb fragment from the 
transgene in SpeI digested genomic DNA. Transgenes containing the LacZ 
cDNA were genotyped using the PvuI 500bp LacZ fragment to screen for the 
3.2kb fragment from the EcoRI digested genomic DNA. 
To determine genotypes by PCR of putative transgenic mice encoding 
VEGF we used the following oligos: 
HomMusKdrFltupper: GGA GAG ATG AGC TTC CTA CAG C 
HomKdrFltlower: TTG CTC TAT CTT TCT TTG GTC TGC. 
These oligos strategically flank the myc tag within the transgene producing a 
~100 bp product in the presence of the transgene. They also flank the intron in 
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the endogenous allele, but not with 100% homology, producing a larger ~450 bp 
product. The touchdown strategy favors the production of the transgene product 
if present, since oligos preferentially bind there due to their homology, but 
ultimately the conditions also allow the endogenous band to be produced. The 
presence of the band representing the endogenous allele verifies that DNA 
samples from animals not carrying the transgene are able to produce a PCR 
band can truly be labeled negative instead of a null result. To achieve both bands 
we use a touchdown PCR as follows: 95°C 5 minutes; 95°C 20 seconds, 55°C 20 
seconds (-1°C per cycle), 72°C 30 seconds, 15 cycles; 95°C 20 seconds, 40°C 
20 seconds, 72°C 30 seconds, 21 cycles; 72°C 5 minutes, 4°C.  
The LacI repressor mice were genotyped with the following oligos, 
lacIfor: CGA TGT CGC AGA GTA TGC CGG T and 
lacIrev: CAC CAG TGA GAC TGG CAA CAG CTG. PCR was performed as 
follows: 94°C 2 minutes; 94°C 20 seconds, 60°C 20 seconds , 72°C 60 seconds, 
30 cycles; 72°C 5 minutes, 4°C. The ~1kb band indicated a positive genotype. 
To determine the genotypes of the putative PTA mice the following oligos 
were used, tts1: GAG GTC GGA ATC GAA GGT TTA AC and  
tts2: GCT CCA TCA CGA TGG ACC AGT AA. PCR was performed as follows: 
94°C 2 minutes; 94°C 20 seconds, 54°C 20 seconds, 72°C 30 seconds, 30 
cycles; 72°C 5 minutes, 4°C. The ~250bp band indicated a positive genotype. 
The LacZ responder mice were genotyped with the following oligos, 
tetLZfor: ATA GGA ACC AGC CTC CTC TCT and 
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tetLZrev: AAG GAC ACT GTT GTT GGT GGT A. PCR was performed as follows: 
94°C 2 minutes; 94°C 20 seconds, 51°C 20 seconds , 72°C 30 seconds, 30 
cycles; 72°C 5 minutes, 4°C. The ~420bp band indicated a positive genotype. 
 
Tissue preparation and histology 
 Digestive organs or isolated pancreata from varying embryonic and adult 
stages were dissected in phosphate-buffered saline (PBS; 2.7 mM KCl, 14.7 mM 
KH2PO4, 136.9 mM NaCl, 8.1 mM Na2HPO4*7H2O, pH 7.4) and fixed 
immediately in 4% paraformaldehyde (pH 7.4) in PBS at 4°C for either two-three 
hours (paraffin embedding) or overnight (frozen embedding). For paraffin 
embedding, tissues were dehydrated in an increasing ethanol concentration 
series followed by two xylene washes, infiltrated with xylene:paraffin (1:1, v/v) 
and two changes of paraffin at 56°C, and embedded for sectioning. For frozen 
embedding, tissues were partially dehydrated in 30% sucrose in PBS overnight 
at 4°C, passed once through 15% sucrose PBS/ 50% OCT media (VWR), 
embedded in OCT media, and stored at -80°C until cryosectioned. 
To detect LacZ reporter expression, β-galactosidase (β-gal) activity was 
detected using X-gal as previously described (Wu et al. 1997) with minor 
modifications. Following fixation, pancreata were washed two times for 30 
minutes each in permeabilization solution (2.0 mM MgCl2, 0.01% sodium 
deoxycholate, 0.02% NP-40 in PBS). Samples were then incubated overnight at 
room temperature in X-gal staining solution (1 mg/mL X-gal, 2 mM MgCl2, 5 mM 
potassium ferricyanide, 5 mM potassium ferrocyanide, 20 mM Tris, pH 7.4), post-
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fixed in 4% paraformaldehyde in PBS at 4°C for one hour, and dehydrated for 
embedding as above, substituting isopropanol for xylene to minimize leaching of 




 Paraffin sections (7 µm) were deparaffinized in xylene and rehydrated in a 
decreasing ethanol series to distilled water. Frozen sections (7 µm) were thawed 
to room temperature. Sections were permeabilized in 0.1% Triton in PBS for 15 
minutes at room temperature, then incubated with blocking solution: PBS with 
1% bovine serum albumin (BSA; New England Biolabs) and 5% normal donkey 
serum (NDS; Jackson Immunoresearch). Primary antibodies were used at the 
following dilutions in blocking solution: guinea pig anti-insulin (1:1000, Linco; 
recognizes all forms of insulin), rabbit anti-glucagon (1:1000, Linco), rat anti-
PECAM (1:200, BD Pharmingen), mouse anti-myc (1:25-1:500, 9E10, Abcam), 
and rabbit anti-hVEGF (1:50, Lab Vision, Ab-8). All primary antibodies were 
incubated overnight at 4°C in a humidified chamber.  
For fluorescent detection of protein, primary antibodies were detected by 
species-specific donkey secondary antibodies conjugated with Cy2, Cy3, or Cy5 
fluorophores (1:500, Jackson Immunoresearch). Fluorophores were excited at 
the appropriate wavelength using either an Olympus BX41 research microscope 
or a Zeiss LSM 510 confocal microscope. For non-fluorescent detection of 
protein, anti-mouse secondary antibodies conjugated with horseradish 
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peroxidase (HRP; 1:500, Promega) were used to detect primary antibody, and 
colorimetric detection of HRP was facilitated by the addition of diaminobenzidine 
(DAB) peroxidase substrate with nickel chloride to produce a gray-black 
precipitate, per manufacturer’s recommendations (Vector Laboratories). Tiff 
images were captured using either MagnaFire software (Optronics) or LSM 
Viewer (Zeiss), and image tonal range and brightness were minimally adjusted 
using Adobe Photoshop.  
 
Pancreatic extracts and measurement of insulin content 
 
 Pancreata from perinatal and adult mice were dissected, weighed, and 
homogenized in acid alcohol for extraction of insulin (Brissova et al. 2002). 
Insulin content from acid alcohol-extracted pancreas was measured by solid-
phase radioimmunoassay (125I-insulin, Diagnostic Products) for mouse anti-
insulin (MP Biomedical). For pancreatic extracts, average insulin concentration 
was calculated as a function of total protein from pancreatic extracts.  
 
Statistical analyses 
All statistical analyses were performed by two-tailed Student’s t-test using 
Excel software (Microsoft).  
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Results 
The goal of the investigation was to determine the window of competence 
during pancreas development that is responsive to VEGF signaling. Specifically, 
the changes in pancreatic endocrine cell development were to be examined. The 
strategy was to overexpress VEGF in the pancreas during different stages of 
pancreatic development. Initially, to have exogenous temporal control of 
transgene expression, the lactose inducible system was employed (Figure 22). It 
was necessary to create a responder allele for this system to be used in the 
study. 
 
Figure 22. Lactose inducible system diagram depicting predicted expression 
outcome and construct design. In the absence of the lactose repressor (LacI) the 
transgene’s expression is mediated by the Pdx1 4.3kb fragment, which spatially 
restricts expression to the endogenous Pdx1 expression domain. In the presence 
of a transgene expressing LacI, expression should be repressed since binding of 
these proteins to their target will physically interfere with transcription machinery. 
Upon addition of IPTG, the LacI protein will preferentially bind to IPTG and not to 
its DNA binding site, thus allowing for transcription. 
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Lactose Inducible System 
To create and validate the responder allele initial design, we utilized a 
well-characterized expression cassette (Sasaki and Hogan 1996; Gannon et al. 
2000; Zhang et al. 2005), inserted the cDNA for the β-galactosidase reporter 
cDNA (LacZ), and inserted three copies of the lactose operator sequence (LacO) 
in tandem 220bp downstream of the transcription start site (Figure 23A). The 
design was created and approved in collaboration with Heidi Scrable, a leader in 
the field of in vivo lactose inducible systems (Cronin et al. 2001; Scrable 2002; 
Cronin et al. 2003). Three founders were generated and their offspring were 
characterized for LacZ reporter expression. In this system, transgenic responder 
animals are both temporally and spatially controlled by cis-regulatory elements 
within the transgene expression cassette in the absence of a transgenic driver 
allele. Therefore, transgenic offspring should express LacZ temporally and 
spatially under the control of the Pdx1PB fragment, which should be detectable in 
the β cells of the pancreas after birth (Gannon et al. 2000; Gannon et al. 2001; 
Van Velkinburgh et al. 2005; Zhang et al. 2005; Wiebe et al. 2007). Reporter 




Figure 23. Diagram depicting expression cassettes constructed for the testing 
and creation of a transgene that can be controlled by the lactose inducible 
system. A. VEGF expression cassette without lactose repressor binding sites 
(lacO) referred to as “no operator”. B. VEGF expression cassette with lacO sites 
in tandem (courtesy of Elizabeth Tweedie) referred to as “old vector”. C. VEGF 
expression cassette with a commercially designed intron sequence containing 
three strategically positioned lacO sites (Stratagene) referred to as “I3”. D. VEGF 
expression cassette with a rous sarcoma virus (RSV) minimal promoter and 
intron wherein the transcription start site is optimally flanked by lacO sites to 
control expression referred to as “RSV”. 
 
This original design for temporal control had limited success in vivo 
perhaps due to inadequate spacing between operators, and attempts at creating 
an improved cassette were unsuccessful. Instead, commercially available lactose 
inducible cassettes (Stratagene) were obtained, and the repressible elements 
within these commercial vectors were inserted into the existing vector. These 
elements included an intron sequence with three optimally positioned LacO 
sequences (I3) and a rous sarcoma virus minimal promoter and intron 
 78
combination with three optimally positioned LacO sequences (RSV). Both of 
these elements were empirically shown to function within their expression 
cassette (Stratagene). These elements were cloned into the VEGF expression 
vector to replace their functionally equivalent sequence (Figure 23). The I3 
sequence was subcloned to replace the β-globin intron in the expression 
cassette, generating the Pdx1I3VEGF expression vector (Figure 23C). The 
HSP68 promoter and beta-globin intron were replaced with the RSV sequence, 
generating the Pdx1RSVVEGF expression vector (Figure 23D). To control spatial 
expression of these transgenes, the 4.3kb Pdx1 enhancer was subcloned 
upstream of the promoter. This enhancer fragment directs early pancreas-wide 
expression consistent with the previously described VEGF overexpression 
studies in the pancreas (Lammert et al. 2001).  
The expression cassettes were screened via transient transfections in 
HEK293 and βTC3 cells lines. VEGF expression from either the Pdx1I3VEGF or 
Pdx1lacOVEGF expression cassette as measure by ELISA was similar in the 
HEK293 cells (Figure 24A). Cotransfections of the Pdx1I3VEGF or 
Pdx1lacOVEGF expression cassette with the equimolar amounts of the LacI 
expressing vector did not significantly repress either expression cassette in the 
HEK293 cell line. Derepression could not be interpreted in this experiment since 
repression was not achieved. Repeating this experiment in βTC3 cells with 
threefold higher amounts of LacI expressing vector revealed the ability of this 
expression system to function in vitro (Figure 24B). The Pdx1I3VEGF expression 
cassette was repressed when cotransfected with the LacI expressing vector and 
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this repression was alleviated upon addition of IPTG to the media. Repression 
was also observed for the Pdx1lacOVEGF upon cotransfection with LacI 
expressing vector, but not as greatly as Pdx1I3VEGF (Figure 24B). The 
Pdx1RSVVEGF expression cassette had low expression in these cells and 
repression/derepression was insignificant (Figure 24B). Since testing VEGF 
expression revealed that the Pdx1I3VEGF responder expression cassette 
expresses, and can effectively be repressed and derepressed (Figure 24), this 
construct was used to prepare transgenic mice, from which we received three 
founders (Figure 25). One founder never produced offspring, and could not be 
included in the investigation. 
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Figure 24. VEGF Expression detected in the media of transfected cells. Cells 
transfected with VEGF expression constructs (Expressed), cotransfected with a 
Lac repressor expressing vector (Repressed) and with the addition of IPTG 
(DeRepressed). A. VEGF expression in HEK293 cells cotransfected with 
equimolar amounts of Lac repressor. B. VEGF expression in βTC3 cells 






Figure 25. Southern blot of genomic DNA isolated from putative transgenic 
founder mice harboring the Pdx1 “I3” VEGF transgene. Predicted 3.2kb fragment 
is consistent with positive controls in the first and third lanes. Both founder 




Previously, transgenic mice overexpressing VEGF in the pancreas via the 
Pdx1 enhancer/promoter fragment were shown to have islet hyperplasia and 
increased β cell mass in two month old mice (Lammert et al. 2001). To compare 
this phenotype to the Pdx1I3VEGF transgenic mice, similar ages were examined. 
All founders obtained were bred with wild type (B6D2) mice and with transgenic 
mice expressing the lactose repressor (LacI) under the control of the β-actin 
promoter (Cronin et al. 2001). The pancreata of these mice were assayed for 
total insulin content (Figure 26). Successful expression should be characterized 
by an increase in total insulin content, consistent with the previously described 
increase in β cell mass (Lammert et al. 2001). There was no change in total 




Figure 26. Pancreatic insulin content of transgenic mice compared to wild type 
littermate controls. No change in pancreatic insulin content was observed. 
Student T-tests were used to measure significant changes of transgenic animals 




It was possible that the endocrine mass may have changed without a 
concomitant change in total insulin content. As such, the islets within pancreatic 
sections were examined from transgenic animals and their littermate controls. 
There was no change in islet size or islet vasculature in either line. Consistent 
with this result, transgene expression was not detected in the pancreas sections 
of these animals via immunofluorescence. Pancreatic protein extracts were 
collected from these animals and analyzed via western blot with two different 
antibodies that target the VEGF produced by the transgene. Since the VEGF 
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produced is the human isoform and contains a myc tag, the anti-human VEGF 
(hVEGF) and the anti-myc antibodies were used. The anti-hVEGF antibody is 
polyclonal and cross-reacts with at least three endogenous isoforms of mouse 
VEGF (Figure 27). The VEGF produced from the transgene is 21kd, slightly 
larger due to the myc tag than the 19kd endogenously produced mouse VEGF 
homolog. The protein extract from one adult pancreas carrying both the driver 
LacI transgene and the responder Pdx1I3VEGF transgene produced a band of 
consistent size on the western blots with the anti-myc and the anti-hVEGF 
antibody (Figure 27, lane1). This result was not reproducible, however. In 
addition, expression of the responder VEGF transgene in this mouse should be 
repressed due to the presence of the driver LacI allele, since IPTG is absent 
(Figure 22). Taken together, the absence of an islet phenotype and the fact that 
transgene expression is detectable, despite the presence of lacI, strongly 
suggested that the responder transgenic animals were not going to be useful for 




Figure 27. Western blot of pancreatic extracts from two month old mice. 
Genotypes of mice are demarked as “+” if they carry the given transgene: VEGF 
for Pdx1I3VEGF and LacI for Beta-Actin LacI (Scrable lab). A. Mouse anti-myc 
(9E10). B. Rabbit anti-hVEGF (Neomarkers). Solid arrows correspond with band 
size consistent with slightly larger transgene generated hVEGF-myc. White arrow 
corresponds with band size consistent with cross reaction with endogenous 




Tetracycline inducible system 
The next approach was to use the tetracycline inducible system. One 
deciding factor was that the transgenic animals needed for this study already 
existed and were readily available. Three Pdx1 tet driver (PTA) mice lines were 
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obtained from Guoqiang Gu (Vanderbilt University). The lines were not yet 
completely characterized, therefore it was critical to determine which line induced 
the best expression in the presence of doxycycline and permitted the least 
expression in the absence of doxycycline (Figure 28).  
 
 
Figure 28. Transgenic mice for the temporal control of expression within the Pdx1 
expression domain. Driver transgenic mice (PTA) express the tetracycline 
suppressor protein (tTS) and the tetracycline dependent activator protein (rtTA) 
under the control of the Pdx1 promoter. They are expressed in a dicistronic 
message utilizing an internal ribosomal entry site. In the absence exogenous 
doxycycline tTS binds to the tetracycline response element (TRE) of the 
responder transgene, suppressing transcription. In the presence of doxycycline, 
rtTA binds to the TRE, displacing tTS and activating transcription. The 
expression through responder transgene is mediated by the cytomegalovirus 
promoter (CMV) and expresses Angiopoietin 1 (Ang1) and Beta-galactosidase 
(LacZ), the reporter, in a dicistronic message. 
 
 
All three lines were crossed with the previously characterized transgenic 
LacZ responder mice (Ward et al. 2004; Ward et al. 2004), which were provided 
by Al Powers (Vanderbilt University). Control of responder allele expression in 
the absence or constant presence of the doxycycline inducer was assessed at 
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P1. All three PTA lines produced offspring that included mice that were double 
transgenic (bigenic) for the PTA driver and LacZ responder allele. In the absence 
of exogenous inducer, in all the offspring, LacZ expression was never observed 
(Table 1A). This was consistent with the anticipated result, suggesting that the 
driver PTA transgene repressed responder allele expression in the absence of 
the inducer (Figure 28).  
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Table 1. Analysis of the tetracycline inducible system using the transgenic lines 
expressing rtTA and tTS under the control of the Pdx1 promoter. Offspring were 
collected after (A) no doxycycline treatment and no offspring had detectable 
reporter staining, (B) 2 mg/mL doxycycline treatment and no offspring had 
detectable reporter staining, and (C) 10 mg/mL doxycycline treatment and no 
offspring had detectable reporter staining. 
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Administration of 2mg/mL doxycycline in the drinking water of the 
pregnant females throughout the duration of their pregnancy did not induce LacZ 
expression in the offspring (Table 2B). Although, PTA line #6 did not produce 
bigenic offspring in this experiment, PTA line #3 and #7 did, and yet there was no 
detectable LacZ expression. This was not consistent with the anticipated result. 
In the presence of the doxycycline, the bigenic animals at P1 should have had 
detectable LacZ expression within the Pdx1 domain (Figure 28). The experiment 
was repeated with an elevated dose of doxycycline (10mg/mL) administered in 
the drinking water throughout the duration of pregnancy. All three PTA lines 
produced offspring including bigenic animals. In all cases, no detectable LacZ 
expression was observed (Table 1C). Again, this was inconsistent with our 
anticipated result. Bigenic animals in the presence of the inducer should have 
had detectable levels of LacZ responder expression (Figure 28). Induction from 
these lines was undetectable, despite the elevated amount of doxycycline. These 
experiments suggested that the PTA driver transgenic mice were not able to 
induce expression during embryonic stages. As such, they were not useful to the 
investigation of VEGF overexpression in the developing embryonic pancreas. 
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Discussion 
Investigations using genetically modified organisms can be a very 
powerful means to elucidate a genetic pathway. Historically, these investigations 
have been performed with gain or loss of gene function. Gain of function 
rudimentarily consists of gene overexpression controlled both spatially and 
temporally by a specific enhancer and/or promoter region. Typically, in these 
systems the investigator has no exogenous control over expression once the 
genetically modified animal has been generated. 
With the advent and implementation of recombinase technology, gain and 
loss of function analysis in whole animals has improved, since in this system 
spatial and temporal expression is controlled by both the recombinase 
expressing allele and the targeted allele. Therefore, by having different 
combinations of recombinase expressing alleles and targeted alleles a greater 
number of spatial expression studies can be investigated. However, once a 
mouse is generated, the investigator has little exogenous control of spatial or 
temporal expression within the animal using this methodology. This shortcoming 
was overcome by the creation of the Cre recombinase and estrogen receptor 
fusion protein (Cre-ER)(Garcia and Mills 2002). This recombinase is sequestered 
to the cytoplasm until tamoxifen is present, wherein the tamoxifen binds to the 
fusion protein, allowing it move to the nucleus where it can act on the target 
allele. This modification allows similar spatial and temporal control to the 
standard Cre recombinase system except that temporal control of recombinase 
activity is controlled exogenously by the investigator by means of the addition of 
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tamoxifen. The shortcoming that remains in this system is the inability to revert 
the system back to its original state once modification occurs. For example, if the 
recombination event causes gene loss of function within the target allele then the 
allele function cannot be restored. 
Both the lactose inducible and the tetracycline inducible system have the 
potential to overcome this shortcoming. All three systems share similar design 
properties in that one driver allele expresses at least one protein that controls 
expression of a second target responder allele. In addition, the proteins that arise 
from the driver allele can be temporally controlled exogenously by the 
investigator upon addition of the inducer molecule. The potential advantage of 
the lactose inducible and the tetracycline inducible system is that upon removal 
of the inducer molecule the driver allele reverts to its uninduced state. 
 
Lactose inducible system 
The advantage of the lactose inducible system compared to the 
tetracycline inducible system is that temporal expression can be more tightly 
controlled. Induction of the targeted allele in animals with this system can be 
observed within four hours after application of the inducer, IPTG, to the drinking 
water of mice (Cronin et al. 2001). Expression can be reverted 24 hours after 
removal of the inducer, which may be attributed to the physical nature of IPTG in 
that it is not fat-soluble (Cronin et al. 2001). In addition to this tight temporal 
control, the inducer crosses the placenta in mice, allowing for embryonic 
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investigations (Cronin et al. 2001). Together, these properties are advantageous 
when investigating narrow time spans during mouse development. 
At the outset of the current investigation, the lactose inducible system 
seemed the most advantageous, the system had been better characterized in 
mice, and the transgenic mice expressing the driver allele were readily available. 
The only tool necessary to utilize this system was to create a responder mouse 
specific to the investigation. The initial design and creation of a responder allele 
was unsuccessful, as expression was undetectable, and was perhaps due to 
construct design (Figure 23). 
Upon reevaluation of the transgene expression cassette design, it was 
determined that the position of the lactose operator sequences relative to each 
other was critical to their function. The 23 bp operator sequences should be 
optimally placed either 70.5, 92.5 or 115.5 bp apart, center to center for ideal 
lactose repressor protein (LacI) binding (Muller et al. 1996). These optimal 
distances are separated by 12 bp increments, which is consistent with one full 
turn of a DNA double helix. These distances allow the LacI dimers that bind the 
individual operators to optimally form a tetrameric complex, since they are close 
enough to be in physical contact with each other, but far enough for the DNA to 
bend allowing for tetramer formation (Lewis et al. 1996). A third operator site, 
placed either 5’ or 3’ to the other two, also participates in repression of 
expression of the DNA sequence, but spacing does not appear to be as critical 
for this site (Reznikoff et al. 1974; Pfahl et al. 1979). LacO placement relative to 
the transcription start site was also critical to functionally critical, with optimal 
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placement at or immediately flanking the transcription start site (Brown et al. 
1987). 
The suboptimal placement of the LacO sites in our expression cassette 
did not necessarily explain the inability of our transgenic lines to express the 
LacZ reporter. In fact, suboptimal placement of LacO sites in the transgene 
cassette more likely causes an inability to repress this responder transgene in 
the presence of the LacI driver transgene. Since expression was not detected in 
any of these responder LacZ transgenic lines independent of the LacI driver 
transgene, repression was a moot point. In addition, the absence of expression 
from these responder LacZ transgenic lines had to be interpreted as a null result. 
The absence of expression could not necessarily be attributed to the LacO 
position alone. For example, although unlikely, the absence of expression could 
also be due to position affect variegation. 
With the criteria regarding the LacO placement, the expression cassette 
was redesigned and constructed. Instead of the LacO being placed suboptimally 
in tandem 220 bp downstream of the transcription start site, they were to be 
inserted flanking the transcription start site of the HSP68 promoter of our 
expression cassette using a PCR strategy (Young and Dong 2004). Ultimately, 
this strategy failed to yield the desired sequence and was substituted. Instead, 
plasmids from the LacSwitch (Stratagene) inducible system were obtained, which 
contained elements within the expression cassettes that had optimally placed 
lactose operator sequences, consistent with the criteria necessary for inducible 
expression. These expression cassettes were assayed with an ELISA for VEGF 
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expression, repression, and derepression via transient transfections in βTC3 and 
HEK293 cell lines. The Pdx1I3VEGF expression vector was the only vector that 
had significant expression, repression, and derepression (Figure 24). This vector 
was therefore used to generate responder transgenic mice. 
Three transgenic founders were identified, but only two generated 
offspring (Figure 25). Neither transgene expression nor anticipated phenotypic 
characteristics were observed (Figure 26, Figure 27). As with the initial strategy, 
it may be possible that these effects were due to position effect variegation. 
Ultimately, it seems more likely that introduction of LacO sequences intrinsically 
negatively affected expression via interference with transcription or translation, 
and overcoming this obstacle may be specific to an individual responder 
expression cassette. 
 
Tetracycline inducible system 
In parallel to the attempt to create a tightly regulated inducible VEGF 
expression system, investigators from other institutions had advanced the tools 
and technology associated with the tetracycline inducible system in pancreata 
(Holland et al. 2002). Initially it was decided this system was inadequate for this 
investigation, due to its lack of technological development and because of its 
inability to tightly control expression. The inducing agent in this system, 
doxycycline, is fat-soluble and takes over two days to leave the system. The 
driver mouse in this system can either express the tetracycline-regulated 
transactivator protein (tTA), which activates responder expression only in the 
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absence of doxycycline, or the tetracycline activator (rtTA) and suppressor (tTS) 
protein, which activates responder expression in the presence of doxycycline, but 
suppress expression in the absence of doxycycline. Therefore, either expression 
can be initiated rather quickly and not rapidly “turned off”, or expression can be 
stopped quickly and not “turned on” rapidly, depending on the driver allele 
utilized.  
The available genetically modified driver mouse line developed and 
characterized was a knock-in of the tetracycline-regulated transactivator in the 
Pdx1 locus, which replaced the Pdx1 coding region in this allele (Holland et al. 
2002). There were two specific problems associated with using this mouse for 
our investigation. First, as previously mentioned the timing of expression could 
not be tightly controlled due to practical limitations of doxycycline administration. 
Second, animals harboring the driver tTA would intrinsically be heterozygous for 
Pdx1. This was of particular importance to the study, since insulin-producing β 
cell function is compromised in Pdx1 heterozygous animals (Brissova et al. 
2002). The changes in specification, differentiation, and proliferation of β cells 
due to changes in VEGF signaling are the desired measurements to be made 
during this investigation, and at the outset, these properties might be influenced 
by a decrease in Pdx1. It is possible to control for the partial loss of Pdx1 by 
comparing results to Pdx1 heterozygous animals, except if Pdx1 itself were 
involved in the signaling pathway, then a potential phenotype might be masked. 
For example, if expression of the VEGF responder transgene was verified and 
appropriate, but in all cases there was no detectable change in β cell 
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phenotypes, then it would be impossible to exclude the Pdx1 heterozygous 
genotype as contributing to the apparent lack of a VEGF response. 
These shortcomings were potentially overcome by the generation of PTA 
transgenic lines designed to express the tetracycline activator and tetracycline 
suppressor as a dicistronic message under the control of the Pdx1 promoter 
(Guoqiang Gu, Vanderbilt University). These PTA mice made it possible to 
perform the investigation without directly compromising endogenous Pdx1 
expression. Three PTA transgenic mouse lines were crossed with mice carrying 
the LacZ responder allele (Ward et al. 2004; Ward et al. 2004). Induction of 
reporter expression was never observed, despite even elevated levels of 
doxycycline (10 mg/mL; Table 1) 
The LacZ responder allele used in this investigation also carried the 
Angiopoietin1 (Ang1) cDNA as part of the dicistronic message (Figure 28). The 
effect of Ang1 expression was of potential interest, since it signals to vascular 
endothelial cells, but was not the principle goal of this investigation. Although it is 
possible that the Ang1 expression from the responder allele could have indirectly 
compromised the characterization of the PTA driver mice, this is unlikely since 
the whole-mount vasculature morphology was unchanged, which is a target for 
Ang1. In addition, the driver allele and the responder allele expression should 
arise from the endodermally derived pancreatic tissue, which was unchanged 
and not known to be directly responsive the Ang1. 
Since with all three PTA driver lines, LacZ reporter expression was 
undetectable under any condition in P1 bigenic animals, we concluded that for 
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exogenous temporal control of VEGF during embryological investigations, the 
appropriate genetic tools were not available. It may be possible to use another 
existing transgenic driver line under the control of the insulin promoter, RIP-rtTA 
(Efrat et al. 1995). Although in this case, the goals of this investigation would be 
compromised in at least two ways. One, the expression would only occur after 
cells had been specified to the endocrine lineage. Two, the expression pattern 
would be within a smaller subset of cells and tend to occur much later in 
development. Due in part to the aforementioned constraints, the committee 






NEITHER ACTIVATION OF VEGF RECEPTOR 1 NOR 2 IS SUFFICIENT TO 





The previous chapter detailed the efforts to create a transgenic mouse line 
with which the VEGF overexpression in the pancreas could be temporally 
controlled exogenously. In this chapter, VEGF signaling was examined to 
elucidate the contribution of the VEGF receptors and their corresponding 
downstream signaling pathways to the induction of endocrine cells in the 
pancreas. 
To determine through which receptor VEGF stimulates pancreatic 
endothelial cells to secrete an endocrine inducing factor(s), we obtained 
receptor-selective VEGF variants from Genentech (South San Francisco, CA). 
These variants were designed based on the crystal structure of the receptor 
binding domain of VEGF interacting with its receptors and contain alterations in 
residues thought to be important for mediating binding to each specific receptor 
(Li et al. 2000). The fltsel variant shows a 470-fold reduction in binding to 
VEGFR2 while retaining wild-type affinity to VEGFR1, while KDRsel shows a 
2000-fold decrease in binding to VEGFR1 while retaining wild-type affinity to 
VEGFR2 (Table 2). Each variant has been shown to specifically activate the 
appropriate downstream signaling pathways (Li et al. 2000; Gille et al. 2001). 
These distinct pathways are useful to determine whether VEGF stimulation of 
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VEGFR1 or VEGFR2 (or both) is responsible for the increase in VEC-mediated 
endocrine induction seen in animals with increased VEGF expression (Lammert 
et al. 2001).  
 
 
Table 2. The Kd values and relative binding affinities of wild type VEGF and 
receptor-selective VEGF mutants (Gille et al. 2001). 
VEGFR2 binding  VEGFR1 binding  
Mutants Kd Relative to VEGF165 Kd Relative to VEGF165 
 pM  pM   
VEGF165 97 1 37 1  
KDR-sel (VEGFR2sel) 100 1 87,000 2,000  
Flt-sel (VEGFR1sel) 12,416 128 98 2.6 
 
 
We anticipated that, similar to other systems, selective activation of 
VEGFR2 in the pancreas would result in increased endothelial cell proliferation 
and thus increased vasculature, while selective activation of VEGFR1 would not 
(Figure 29). Increased vasculature should in turn result in increased production of 
a putative endocrine inducer. Therefore selective activation of VEGFR2 in the 
pancreata of mice should have a similar phenotype to the overexpression of 
VEGF in the pancreas in that there will be an increase in islet vascular density. In 
contrast, overexpression of wild type VEGF also activates VEGFR1, which can 
cause secretion of growth factors from VECs (Figure 29)(LeCouter et al. 2003). 
Unlike VEGF overexpression in the pancreas, selective overactivation of 
VEGFR2 would not directly result in VEC growth factor secretion. Therefore, 
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selective activation of VEGFR2 in the pancreata may not result in as large an 
increase of endocrine cells as seen in the VEGF overexpression in the pancreas. 
 
 
Figure 29. Proliferation of hepatocytes versus sinusoidal cells in response to 
selective VEGFR activation. Quantitative analysis of proliferating hepatocytes (A) 
and sinusoidal cells (B) was performed after BrdU immunohistochemistry of liver 
sections from animals treated with Av-LacZ, Av-KDRsel, or Av-Fltsel 10 days 
after Av administration. The VEGFR-1 selective agonist Fltsel results in the 
greatest hepatocyte proliferation but fails to induce sinusoidal endothelial cell 
proliferation. KDRsel is a potent mitogen for sinusoidal cells and also results in 
increased hepatocyte proliferation. Values are means ± SEM. Level of 
significance was assessed by unpaired t tests; P values are indicated (LeCouter 
et al. 2003). 
 
 In contrast, selective overactivation of VEGFR1 does not cause an 
increased proliferation of VECs (Figure 29)(LeCouter et al. 2003). Therefore 
selective overactivation of VEGFR1 in the pancreas should contain a similar 
density of vasculature as wild-type littermates. However, since endogenous 
VEGF stimulation of VEGFR1 results in production of certain growth factors 
independent of VEC proliferation, we predicted that there would be an increase in 
total endocrine cell mass despite the lack of increase in vasculature. This chapter 
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describes the generation and phenotype of transgenic mice overexpressing 
VEGF variants in the pancreas that selectively activate either VEGFR1 or 2. 
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Materials and Methods 
 
Transgene generation 
 Vectors containing the coding sequence for either KDR-sel or FLT-sel 
were obtained as a kind gift from Genentech (Li et al. 2000). Vector containing 
the coding sequence for human VEGF-165 with the internal myc tag (VEGF-myc) 
was previously characterized (Chavand et al. 2001). The coding sequence for 
VEGF-myc was cloned into the pBluescript vector (Stratagene) with BamHI and 
EcoRI. Both the coding region for KDR-sel and FLT-sel were partially digested 
with Nco1 and completely digested with BsmI. The coding fragments were cloned 
into the VEGF-myc vector digested with NcoI and BsmI. The resulting coding 
sequence generated a human VEGF-165 isoform, with an internal myc tag, 
specific for either KDR or FLT, which are referred to as VEGFR2sel or VEGFR1sel, 
respectively. Coding regions were verified by restriction digestion and 
sequencing (Vanderbilt Sequencing Core). 
 PdxPBlacOHNF6 vector was generated in the Gannon lab and kindly 
provided by Elizabeth Tweedie Ables. An HA tag, IRESII eYFP (Clonetech) was 
used to replace the HNF6 coding region. This vector was digested with XbaI and 
ligated to remove the 3xLacO sequence from the 5’ region. The resulting vector 
was digested with BclI and EcoRI to remove the HA tag coding region and 
replace with either the coding region VEGFR2sel or VEGFR1sel digested with 
BamHI and EcoRI. A 9kb XbaI-XbaI Pdx1 genomic fragment was digested with 
XbaI, blunted, and SacI to generate the 4.3kb Pdx1 fragment. This fragment was 
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subcloned into the SmaI/SacI digested phsppolyABSSKII provided by the Hogan 
Lab to generate an insertless expression cassette driven by the 4.3kb Pdx1 
promoter. The SpeI digested VEGFR2sel or VEGFR1sel was subcloned into the 
resulting SpeI digested vector creating the final expression vectors. These 
constructs were verified by restriction digestion. 
The transgene cassettes were maxiprepped and purified by CsCl 
ultracentrifugation. The cassettes were released from the vector backbone by 
NotI restriction digestion, isolated by gel electrophoresis, and purified by gelase 
extraction. The DNA was measured and provided to the Vanderbilt Transgenic 
Mouse / ES Cell Shared Resource for transgenic mouse generation. 
 
Mice 
An inbred hybrid line (B6D2; Jackson Labs) was used for endogenous 
VEGF protein expression studies. For embryonic analyses, the morning of the 
vaginal plug was considered E0.5. Mice were maintained on mouse chow 5015 
(24% fat, 57% carbohydrates, 19% protein; TestDiet) ad libitum. All mouse 
studies were performed in accordance with the Vanderbilt Institutional Animal 




DNA extraction and genotyping 
Mice were genotyped using the same techniques and procedures 
described in the previous chapter since the transgene construction was almost 
identical and shared the region detected in the genotyping technique.  
 
RNA extraction and analysis 
Dorsal pancreata from P1 mice were dissected and immediately placed 
into 5 volumes (~100 µL) of RNAlater (Ambion) and stored at -20°C until 
genotyped. RNA was extracted from tissue using RNAqueous (Ambion), DNA 
contamination was reduced using TURBO DNA-free (Ambion), and cDNA was 
prepared with or without reverse transcriptase using SuperScript (Invitrogen) all 
according to manufacturers’ specifications. 
To assay for the presence of the transcript, the following oligos were used: 
Hspfor: GCG GAG CGC AGC CTT CCA GA 
Bglobinrev: CAA CCA GCA CGT TGC CCA GGA. 
These oligos flank the β-globin intron of the transgene. One oligo anneals in the 
heat shock minimal promoter (hsp68) and the other anneals 3’ of the β-globin 
intron RNA splice site. The PCR product arising from the transgene mRNA that 
has been properly spliced will be ~100bp, whereas the PCR product arising from 
the genomic DNA or unspliced RNA will be ~350bp. There is no PCR product 
arising from an endogenous locus. 
 In addition, to assay for the presence of the transcript, the genotyping 
oligos described in the previous chapter were used on the cDNA prepared from 
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P1 pancreata. In this case an additional PCR product can be formed that is 
~75bp in length representing the endogenous spliced mRNA. The shortcoming of 
this approach is that the PCR product arising from the transgene transcript is 
identical in size to the PCR product arising from the transgene itself. Therefore 
DNAase treated RNA was used as a control to verify that PCR products did not 
arise from the genomic DNA. 
 
Tissue preparation, histology, and immunohistochemistry 
 Digestive organs or isolated pancreata from varying embryonic and adult 
stages were dissected and processed as described in the previous chapter. 
 
Morphometric analysis 
 Sections of perinatal pancreata were stained at 250 µm intervals along the 
length of the pancreas (at least eight sections per pancreas) for insulin and 
PECAM. Total islet insulin area was quantitated by a threshold of pixel intensity 
using Metamorph morphometric software (Molecular Devices). Total islet PECAM 
area was then determined by threshold of pixel intensity within the insulin+ area. 
Average vascular density was expressed as a percentage of total islet area 
measured.  
 
Physiological assessment of glucose homeostasis 
 Intraperitoneal glucose tolerance tests (IP-GTT) were performed as 
previously described (Gannon et al. 2000). Briefly, eight week old mice fasted for 
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16 hours were given an intraperitoneal injection of filter-sterilized glucose (2.0 mg 
dextrose/g body weight) in PBS. Glucose concentration was measured in tail vein 
blood using the Freestyle glucose meter and test strips (Therasense) before 
injection (time 0) and 15, 30, 60, 90, and 120 min after injection. Blood glucose 
concentrations at time 0 and time 120 were used to classify mice as either 
physiologically normal (fasting < 140 mg/dL; ending < 200 mg/dL), glucose 
intolerant (fasting < 140 mg/dL; ending ≥ 200 mg/dL), or diabetic (fasting ≥ 140 
mg/dL; ending ≥ 200 mg/dL).  
 
Pancreatic extracts and measurement of insulin content 
 




All statistical analyses were performed by two-tailed Student’s t-test using 
Excel software (Microsoft).  
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Results 
Our strategy for this aim was to overexpress either VEGFR1 or VEGFR2 
selective agonist under the control of the Pdx1 4.3 kb enhancer/promoter and 
assay their effects at postnatal day (P)1 and 2 months of age. Transgene 
expression was predicted to be throughout the pancreatic epithelium from early 
bud stages and gradually become enriched only in β cells before birth, similar to 
endogenous Pdx1 expression. These agonists have been developed, 
characterized, and published by a group at Genentech (Li et al. 2000; Gille et al. 
2001). Using partial digestions, a portion of each coding sequence, which 
contained coding variation, was subcloned into the coding sequence for VEGF 
contained in the pBluescript vector. The coding region was verified by 
sequencing, and these constructs were used to create transgenic mice. 
Three transient transgenic founders were generated with the 
Pdx1VEGFR2sel cassette, and two from the Pdx1VEGFR1sel cassette. Pancreata 
from P1 transient transgenic founder mice were collected and their pancreata 
were morphometrically characterized. Mice expressing the VEGFR2 agonist had 
a 49% increase in endothelial to endocrine ratio, but islet size was similar to wild 
type (Figure 30). This robust increase in vascular endothelial cells is exemplified 
in the transient transgenic mouse labelled “K1.7” (Kdr agonist at P1, sample 7), 
where PECAM staining is much denser than in the wild type control (Figure 30). 
There was significant variation in the vascular phenotype observed between 
lines, and this is likely due to variation in expression of the transgene, although 
protein levels were not determined. 
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Figure 30. Representative sections of P1 wild type and Pdx1VEGFR2sel transient 
transgenic pancreata labeled with antibodies for PECAM, Insulin, and DAPI. The 
expression cassette is depicted at the top of the figure and is not to scale. 
 
 
In contrast, pancreatic VEGFR1 agonist expression resulted in a 
decreased vascular density, and the islet size in these transient transgenics was 
not significantly different from the wild type littermate controls (Figure 31). As 
predicted, the endocrine to endothelial cell ratio was increased in these animals. 
This phenomenon is not due to an increase in endocrine cell mass, but instead 
an unexpected decrease in the endothelial cell mass. Since endocrine mass is 
insignificantly changed in these animals, there is likely an alternative mechanism 
mediating the change in endocrine to endothelial cell ratio. 
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Figure 31. Representative section of P1 wild type and Pdx1-VEGFR1sel transient 
transgenic pancreata labeled with antibodies for PECAM, Insulin, and DAPI. The 
expression cassette is depicted at the top of the figure and is not to scale. 
 
 
To resolve the phenotypes and characteristics observed in the transient 
transgenic animals, transgenic lines were generated from the Pdx1VEGFR2sel 
and Pdx1VEGFR1sel cassettes. There were two lines obtained using the 
Pdx1VEGFR2sel cassette, and three lines obtained from the Pdx1VEGFR1sel 
cassette. To examine expression pancreatic expression in these lines, RNA was 
extracted and cDNA created from P1 pancreata of transgenic mice and their wild 
type littermates. Two strategies were employed to detect transgene expression. 
Initially, oligonucleotides were used that flanked the region coding for the myc 
epitope within the VEGF sequence. Comparing DNAase treated and untreated 
samples of the extracted RNA revealed the expected product in the DNAase 
treated sample and not in the untreated samples (Figure 32). Genomic DNA 
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contamination in the extracted RNA would result in the same size product. To 
resolve this, oligos were designed that flanked the transgene intron. The PCR 
product arising from the cDNA of this region is ~100 bp, whereas the PCR 
product from genomic DNA would be ~450 bp. Transgenic lines were screened 
for transgene mRNA expression at P1. All lines examined had detectable mRNA 
levels except Pdx1VEGFR2sel line #28, consistent with the previous detection 




Figure 32. Detection of transgene mRNA in P1 pancreata of transgenic animals 
overexpressing VEGFR1sel or VEGFR2sel. The upper panel shows the presence 
of a band consistent with the transgene with or without reverse transcriptase 
(RT). Endogenous mRNA is only amplified in the presence of the RT. The lower 
panel represents the same samples after DNAse treatment of the extracted RNA. 
In this case there is selective amplification of line 14 transgene mRNA in the 
presence of RT, but not in its absence, indicating transgene expression. Line 28 
amplification pattern is equivalent with or without RT, indicating no transgene 





Pancreata were collected at P1, 1 month and 2 months of age from the 
three Pdx1VEGFR1sel lines and the one Pdx1VEGFR2sel line, which all had 
detectable transgene mRNA expression. These time points were chosen to 
enable the comparison of phenotypes between these mice to the mice 
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overexpressing VEGF under the control of the Pdx1 enhancer/promoter 
(Lammert et al. 2001). VEGF is capable of activating both VEGFR1 and 2, 
therefore Pdx1VEGF animals are a control for the pancreatic phenotype of either 
VEGFR1 or 2 overactivation. Protein was extracted at P1, 1 month and 2 months 
of age from the three Pdx1VEGFR1sel lines and the one Pdx1VEGFR2sel line and 
insulin content was determined (Figure 33). At all time points examined, the 
insulin content was not significantly different from the wild type littermate 
controls. At one month of age, the mice overexpressing VEGFR1sel tended to 
have an increase in the total insulin content, but this was not significantly 
different from their wild type littermates. Moreover, by two months of age the 
mice overexpressing VEGFR1sel did not tend to have an increased insulin 
content. In fact, at this time point no transgenic line had an average total insulin 
content greater than the wild type control. 
Taken together, VEGFR1 and VEGFR2 signaling have distinct roles in 
pancreatic islet development, and the expected expansion of endocrine mass 
mediated by increased VEGF may require increased signaling through both 
receptors, since overactivation of either VEGF receptor alone is not sufficient to 
increase islet size or pancreatic insulin content, despite changes in endothelial 





Figure 33. Total insulin content measured in mice overexpressing VEGF 
selective agonists under the control of the Pdx1 enhancer. Total insulin content 
was not significantly different from wild type at P1, 1 month, or 2 months of age. 
Wild type (WT) littermates are blue, lines overexpressing VEGFR1sel (R1sel5, 11, 
14) in textured red columns, the line overexpressing VEGFR2sel in brown (R2sel 
29). Columns are average +/- SEM extracted insulin (ng) normalized to protein 




The interaction between endothelial cells and endocrine cells during 
development remains a provocative relationship given the effect of VEGF 
overexpression in the pancreas (Lammert et al. 2001). Yet there is mounting 
evidence to suggest this interaction may not be as profound as originally 
suggested (Lammert et al. 2003). In fact, the expansion of endocrine cells in the 
Pdx1VEGF transgenic mouse is more likely the result of increased nutrition 
supplied by the increase in vascular density, than a direct reciprocal signaling 
mechanism between endothelial cells and endocrine cells. For example, 
investigators have overexpressed VEGF under the control of the rat insulin 
promoter (RIP) and observed no change in islet size (Gannon et al. 2002). The 
embryonic expression of VEGF in the RIP-VEGF mice pancreas may be at too 
low of a level or not early enough to significantly affect islet endocrine cell 
specification, but it is unlikely.  
 Unlike in mice, the endothelial cells are not required in zebrafish for the 
induction of endocrine cells in the pancreas (Field et al. 2003). It is possible this 
may be an evolutionary distinction, but the lack of conservation of this 
phenomenon across species undermines its significance. Deletion of the VEGF-
A gene in β cells or pancreas-wide results in a slight reduction in islet size (Inoue 
et al. 2002; Lammert et al. 2003; Brissova et al. 2006). This can be easily 
explained by the reduction in vascular density which decreases the nutrient 
supply to the islet mass. Certainly VEGF secretion from the islet is necessary for 
islet vasculature function given the changes in glucose physiology and 
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endothelial morphology observed in the pancreas tissue specific knockouts, but 
the role of VEGF in a reciprocal inductive signaling event between endocrine 
cells and endothelial cells is not supported by these investigations. 
 Islet VEGF secretion is indirectly important for endocrine cell survival. 
Several islet transplant studies have shown that VEGF secretion by the islet, or 
VEGF added to transplanted or cultured islets, improves the survival of this 
tissue due to its ability to recruit and maintain vasculature (Zhang et al. 2004; Lai 
et al. 2005; Mathe et al. 2006; Cross et al. 2007). The indirect β cell survival role 
for VEGF could also explain the reduction in islet size in the pancreas tissue 
specific VEGF knock out investigations (Inoue et al. 2002; Lammert et al. 2003; 
Brissova et al. 2006). 
 It is possible that VEGF is capable of causing an increase in endocrine 
cell mass by a reciprocal signaling event. In the current investigation we 
observed a significant increase in vascular density without a concomitant 
increase in endocrine cell mass (Figure 30). This is inconsistent with the 
phenotype of the VEGF overexpression throughout the pancreas, where both 
endocrine mass and vascular density was increased (Lammert et al. 2001), 
suggesting that an increase in vasculature alone is not sufficient to increase 
endocrine cell mass. If the role of the vasculature in the developing islet were to 
provide nutrition for growth and proliferation of the endocrine cell mass, then an 
increase in vasculature should increase endocrine mass, but this was not 
observed in mice overexpressing VEGFR2sel in the pancreas at P1 (Figure 30); 
although it is likely this animal would have shown an increase in endocrine mass 
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comparable to that seen in pancreata from animals overexpressing VEGF in the 
entire pancreas if we had collected transgenic pancreata at a later stage. An 
increased endocrine mass at a later stage may be a consequence of increased 
nutrition, due to the increased vascular density. Perhaps the increase in 
endothelial mass observed in mice overexpressing VEGFR2sel in the pancreas at 
P1 does not cause an increase in endocrine mass because the endocrine mass 
has not yet had the opportunity to benefit from increased nutrition. 
 The transgenic animals in this study are still being analyzed in this 
ongoing investigation. Thus far, the evidence in this chapter suggests that VEGF 
signaling in the pancreas requires signaling through both VEGFR1 and VEGFR2 
for expansion of the endocrine cell mass. Alternatively, expansion of endocrine 
mass may be due to a nutritive or survival affect of increased VECs and not an 











Diabetes is due to inadequate signaling through the insulin receptor of 
target tissues, preventing appropriate glucose uptake, but the source of this 
inadequacy can be much more complex.  In both type 1 and 2 diabetes there is 
an ultimate loss of insulin producing cells in the pancreas, and monogenic forms 
of diabetes compromises insulin production from the pancreas. The inadequate 
amount of insulin producing cells in the pancreas has become a focal point for 
therapeutic strategies. In essence, the strategy would be to either cause existing 
cells to generate more or to transplant exogenous glucose-responsive insulin 
producing cells. For either of these strategies to succeed, elucidating the 
endogenous cascade of events that is necessary for a glucose-responsive insulin 
producing cell to normally differentiate may be vital. The intentions of the 
investigations described in this work were to uncover specific molecular events 
and cellular relationships involved in the differentiation of glucose-responsive 
insulin producing cells. 
In Chapter II we uncovered a role for the PTF1 transcription factor 
complex in activating the transcription of the Pdx1 transcription factor.  This 
molecular event occurs very early during development when the pancreas is just 
beginning to form. Although null mutations in either of these transcription factors 
share a similar gross pancreatic phenotype (Offield et al. 1996; Krapp et al. 1998; 
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Kawaguchi et al. 2002), their expression pattern and  function In the mature 
pancreas diverges into separate tissue types, suggesting independent roles for 
these factors during pancreas development. What remains unclear is how 
elevated levels of PTF1 in the pancreatic exocrine tissue fail to activate Pdx1 
expression at levels similar to that of Pdx1 during embryonic development. We 
suggest that this expression is modulated by the change in expression of the 
third isoform of the PTF1 complex from RBP-J to RBP-L, which is coincident with 
the changes in Pdx1 expression. However this proposed mechanism remains 
speculative, and requires continued investigation.  Perhaps the next step would 
be to determine if by chromatin immunoprecipitation a change in occupancy can 
be observed at the PTF1 site of the Pdx1 enhancer. 
Another phenomenon that remains to be elucidated why the Area III 
containing Pdx1XB fragment had early broad expression throughout the early 
endogenous Pdx1 region, but the Area III containing Pdx1I-II-III fragment was 
restricted to the pancreas. In either case the expression in the pancreas can be 
explained by the activity of PTF1 through Area III, but the expanded expression 
of Pdx1XB must be caused by some other factor. It has been demonstrated that 
Hnf6 can bind to Area III of the Pdx1 enhancer (Poll et al. 2006). Since Hnf6 
precedes Pdx1 expression in the foregut endoderm and its expression pattern 
overlaps the early Pdx1 expression, it seems a likely candidate to control this 
early broad expression of Pdx1. However, the Pdx1I-II-III fragment also contains 
the Hnf6 site and does not have the early broad expression pattern outside of the 
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pancreas. To resolve this possibility, it would be prudent to determine if early 
broad expression of Pdx1 is also controlled by Hnf6. 
In Chapter III, we describe the creation and characterization of several 
putatively inducible transgenic animals. Ultimately these attempts were 
unsuccessful, yet some of the questions to be addressed remain. For example, 
what are the critical qualities that an inducible transgene must possess and can 
an inducible transgene be more rigorously and accurately tested in vitro prior to 
its use in vivo, or is the production of a functional inducible transgene a matter of 
chance? These questions are outside of the scope of this investigation, but may 
be addressed or become moot with advancing technology. 
The investigations in Chapter IV coupled with the findings in Chapter III, 
although consistent with each other, were not necessarily consistent with 
previous investigations (Lammert et al. 2001; LeCouter et al. 2003). Since an 
elevated amount of VEGF expression in the pancreas resulted in an increase in 
insulin producing cell mass, we wondered whether this was restricted to either a 
time window or specific step in the differentiation of insulin producing cells. As 
described in Chapter IV, there have been a couple published investigations that 
are inconsistent with this phenomenon (Gannon et al. 2002; Field et al. 2003). 
Our findings in Chapter III and IV are also inconsistent with this phenomenon, but 
fail to be definitive. Further investigation is necessary to determine if endothelial 
cells are indeed sufficient to increase pancreatic endocrine mass via a paracrine 
signaling event. 
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Taken together, our findings suggest that early pancreas cell 
differentiation requires PTF1 to enhance Pdx1 expression, and that signaling 
from endothelial cells may be necessary for Ptf1a expression, but are not 
sufficient. Therefore, if new glucose-responsive insulin producing cells are to be 
produced as a cellular therapy for diabetes, then Ptf1a expression may be 
necessary at early stages of differentiation to recapitulate the enhancement of 
Pdx1 expression that normally occurs, and signaling from endothelial cells may 
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